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Electronic medical records (EMRs) are increasingly being used for patient management in eye 
clinics in the UK. Glaucoma clinics in particular have an increasing capacity to store and link 
patient data from a variety of sources, including perimetric visual field (VF) records, intraocular 
pressure records, medication and surgical records. The studies detailed in this thesis aim to 
show, for the first time, the versatility of these data through a range of proof-of-concept 
examples. The studies were designed to show the different levels of scope that these data can 
be used for, from an individual patient level (patient performance), to a clinic level (auditing 
clinic performance) to disease level (retrospective cohort studies). The studies took advantage 
of two data extractions from EMRs from regionally different National Health Service (NHS) 
Hospital Trust glaucoma clinics in England. The first (2012) and second (2015) extraction 
yielded records from 88954 and 73994 people respectively. Central to these studies was the use 
of more than 1.2 million individual VF examinations. The first study tested the hypothesis that 
perimetric fatigue effects are greater in the eye examined second. The results showed that the 
second eye tested (usually the left eye) showed slightly reduced sensitivity (0.13 dB, p < 0.001) 
in mean deviation (MD) compared to the first eye. There was also a small but significant relative 
increase (3%) in the longitudinal variability of the second eye. This study provides evidence 
for statistically significant fatigue effects on the second eye tested in routine clinics. Although 
the average effect was small, there was a large variation among patients and as such, to keep 
any order effect consistent, eye testing should be carried out in the same order for each visit. 
The second study took routinely collected clinic data and audited aspects of service delivery of 
glaucoma. Metrics predicting loss of sight years and reliability of examinations varied between 
the centres (p < 0.001) indicating that some clinics may be performing better than others. This 
study illustrates the feasibility of assessing aspects of health service delivery in glaucoma 
clinics through analysis of VF databases and the proposed metrics could be useful for blindness 
prevention from glaucoma in secondary care centres. In the third study, the real-world 
conversion rates from ocular hypertension (OHT) to primary open angle glaucoma (POAG) 
were estimated. Within the study population (n = 3163), 17.5% (95% CI: 15.4% - 19.6%) were 
predicted to convert within 5 years. The use of intraocular pressure (IOP) lowering treatment 
was associated with a lower change of conversion with a Hazard Ratio of 0.45 (95% CI: 0.35 
– 0.57, p < 0.001). Previously, it had only been in the context of clinical trials that OHT 
conversion rates and efficacy of IOP-lowering treatment have been reported, however this study 
shows the feasibility of using EMR data as an alternative. In the fourth study, the outcomes of 
patients with a combination of uveitis and glaucoma were compared with that of POAG only 
patients. The uveitis and glaucoma eyes were almost twice more likely to have rapidly declining 
VF function than the POAG only eyes (age-adjusted risk ratio of 1.9 [95% CI: 1.8 – 2.0]). It 
can be difficult to study the outcomes of a combination of diseases such as this due to the low 
incidence rate. However, when patient visits are recorded in EMRs in such large numbers it 
becomes feasible to carry out these retrospective cohort studies. In the fifth study, both previous 
datasets were assessed to investigate how socioeconomic factors affect likelihood of glaucoma 
detection and progression. People in the most deprived regions presented to the clinic with 
worse VFs than those in the more affluent regions. Once patients were diagnosed and treated 
under the management of the hospital eye services these dipartites dissipated. For example there 
was no evidence of differences in the rates of progression (worsening) of VF based on 
socioeconomic factors. In conclusion, the results from these studies show the breadth of 
research that is possible if EMR data from glaucoma clinics were to be fully utilised. Insights 
into individual patient care, the performance of clinics, and the prognosis of diseases could all 
be gained through the analysis of routinely collected data in eye clinics as well as an insight 




1 Introduction to thesis 
This introductory chapter gives an overview of relevant background information that underpins the 
research contained in the thesis. This will begin with a brief introduction to glaucoma, highlighting 
some clinical information that will be helpful in understanding the glaucoma-related studies. Following 
this, a more detailed section describing visual fields (VFs) and some approaches to analysing 
longitudinal VF data. Finally, a section detailing the two main electronic medical record (EMR) datasets 
used in the studies is included.  
1.1  Glaucoma definition and epidemiology 
Glaucoma is the term used to identify a group of irreversible progressive diseases that cause vision loss 
through damage of the optic nerve. It is one of the most common causes of irreversible blindness in the 
world.[1,2] Accelerated death of retinal ganglion cells (RGC), which play a vital role in the transfer of 
visual information from the photoreceptors to the optic nerve, is the primary mechanism of 
glaucomatous damage.  
Glaucoma affects around 3% of the worldwide population aged between 40 and 80 with the prevalence 
of the disease rising as age increases. The number of people living with glaucoma is expected to be 76 
million by 2020.[3] In primary open angle glaucoma (POAG), this damage usually occurs slowly over 
time, often over decades, requiring routine contact with the hospital eye service to ensure adequate 
management. As the life expectancy (and hence population of over 40s) of the UK is increasing, the 
burden on glaucoma clinics is steadily increasing. This thesis is focused on what is happening within 
English clinics only although the findings can broadly be related to the rest of the UK. 
1.1.1 Risk factors & Treatment 
While glaucoma encompasses several different diseases, the work in this thesis will focus on the most 
common type, primary open angle glaucoma. A related term, chronic open angle glaucoma (COAG) is 
a term used that covers variants of OAG with elevated eye pressure (POAG), normal pressure (normal 
tension glaucoma; NTG) and causes of secondary open angle glaucoma associated with pigment 
dispersion and pseudoexfoliation.[4] The NICE guidelines are evidence-based recommendations for 
health and care in England. They set out the care and services suitable for most people with a specific 
condition or need, and people in particular circumstances or settings. Glaucoma is often characterised 
by a raised intra-ocular pressure (IOP), optic nerve head damage and reduced VF sensitivity. There are 
several known risk factors for POAG. In short, these include older age, race, family history, diabetes, 
systemic vascular diseases, ocular perfusion pressure and optic disc area.[5–10] Some genetic factors 
have also been proposed such as the MYOC and OPTN genes.[11–13] The only modifiable risk factor 
however is the IOP.[7,14] In the general population, the mean IOP is around 16 mmHg and two standard 
deviations either side of this gives a ‘normal’ IOP range.[15] People with IOP above this normal range 
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but without detectable glaucomatous damage are referred to ocular hypertensives or glaucoma suspects. 
Conversely, it is possible for patients to have normal IOP but still develop glaucomatous optic disc 
damage and VF loss. This is referred to as normal tension glaucoma (or low-tension glaucoma). 
At present, the detection of glaucoma primarily relies on opportunistic identification with optometrists 
responsible for nearly all referrals to hospital eye service for suspected cases. Referral guidelines for 
ocular hypertension (OHT) or other glaucoma include an IOP of 24 mmHg or more (as measured with 
Goldmann applanation tonometry) as one of the possible diagnostic criteria. [4] Previous guidelines set 
this IOP threshold at 21 mmHg and the EPIC-Norfolk study reported a prevalence of 10% for OHT in 
the English county of Norfolk using this IOP cut-off.[15] Current guidance recommends that IOP-
lowering eye drops or selective laser trabeculoplasty (SLT) may be offered to patients with high IOP if 
they are at risk of visual impairment in their lifetime. A large randomised clinical trial, the Ocular 
Hypertension Treatment Study, showed the efficacy of IOP-lowering treatment on delaying (or even 
preventing) conversion from OHT to POAG.[5,16] Patients with OHT were assigned either to ocular 
hypotensive medication or to a placebo arm. The cumulative 5-year probability of developing POAG 
was reduced in the treatment arm by 60%.  When a patient has already progressed to POAG, two other 
large clinical trials, the Early Manifest Glaucoma Trial and the United Kingdom Glaucoma Treatment 
Study, showed that IOP-lowering medication can slow down the progression of VF damage.[7,17] In 
both of these studies, patients with “early” glaucoma were assigned to either a placebo group or to a 
treatment group receiving ocular hypotensive medication. The frequency of progression as measured 
by VF or optic disc changes was reduced in both intervention arms. These results show the efficacy of 
using IOP-lowering drugs in the treatment of OHT and POAG to reduce progressive VF loss. 
As of 2017, the current National Institute for Health and Care Excellence (NICE) guidelines recommend 
referral to secondary care for glaucoma related conditions under certain criteria. This involves 
assessment for glaucoma-associated signs in the VF (perimetry), IOP (applanation tonometry), optic 
nerve (slit lamp biomicroscopy/OCT) or anterior angle (gonioscopy) measurements. A repeat VF 
assessment and IOP measurement should then be considered before referral, to confirm a VF defect or 
an IOP of 24 mmHg or more. Patients who have been previously discharged from hospital eye services 
for COAG-related conditions should not be referred unless clinical circumstances have changed. 
Treatment may be offered in the form of one or more IOP-lowering eye-drops, surgery or laser treatment 
to lower IOP. Several classes of eye drops are available, all with the aim of reducing IOP by either 
reducing the production of aqueous humour in the eye or by increasing its outflow. Several studies have 
shown the clinical efficacy of these various different types of eyedrops.[17–19] Laser treatment, which 
can often be considered for an initial treatment (a so-called laser first approach), can also reduce IOP 
by increasing outflow.[20] A major trial showing the efficacy and cost effectiveness of SLT concluded 
that it should be offered as a first-line treatment.[20,21] Glaucoma surgery for refractory IOP is a 
relatively last resort option compared to less invasive treatments, of which, trabeculectomy is 
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considered the gold standard. A hole is cut into the wall of the eye (sclera) to allow for additional 
drainage of the aqueous humour. 
1.1.2 Detecting and monitoring POAG 
The structure-function relationship between changes in the optic nerve and how that translates into 
functional VF changes is unclear.[18] In certain cases, structural damage can be severe with only a mild 
change in VF function. Even when there is significant VF loss, the patient might not experience any 
difference in their day-to-day vision until it is very severe.[19] In this way, early to moderate glaucoma 
is said to be asymptomatic. Many glaucoma patients do not notice loss of their VF due to the nature of 
the damage: VF loss in the one eye can also be compensated by better vision in the fellow eye. As such, 
routine contact with primary eye care professionals is the most important way of catching glaucoma 
early and retarding loss of vision function. The number of cases of glaucoma worldwide is expected to 
increase with population increases.[3,20,21] As such, efficient referral schemes and efficient 
management of patients in glaucoma clinics will become increasingly important in years to come. 
Diagnostic evaluation of glaucoma severity consists of an examination of the anterior chamber angle 
using gonioscopy, IOP measurements (ideally using applanation tonometry), examination of the visual 
field with perimetry and imaging of the retinal nerve fibre layer and of the optic nerve head.[22] After 
diagnosis, glaucoma requires lifelong monitoring which is typically carried out in secondary care. As 
glaucomatous damage is irreversible, the management aim is to delay the progression of the disease. 
IOP is currently the only modifiable risk factor for glaucoma and, as such, the main aim of glaucoma 
care is to lower IOP. After a patient is diagnosed with glaucoma, a target IOP pressure is decided upon. 
This is an estimate of IOP that, given the patient’s age and disease severity, should be enough to prevent 
progressive VF loss that could cause a reduction in quality of life. As mentioned above, there are several 
options available to manage IOP levels. Functional and structural measurements are also taken at each 
clinic visit, typically through the use of standard automated perimetry and fundus photography/ocular 
coherence tomography, respectively. Ideally the monitoring interval should reflect the patient’s 
individual condition, with higher risk patients being seen more frequently and low risk patients less 
so.[22] It is not clear however whether this is the case.[23]  
1.2 A primer on visual fields 
Simply put, the VF is the entire area that can be seen when the eye is directed forward.at a single object. 
The maximum extent of the VF is about 65 degrees superiorly 75 degrees inferiorly, 100 degrees 
temporally and 60 degrees nasally.[24] Within this range, and under photopic conditions, the greatest 
sensitivity corresponds to the fovea, with a decline in sensitivity as with increase in sensitivity. This 
can be helpfully depicted as an “island” or “hill” of vision with a steep central peak (Figure 1.1). 
Measuring this “hill” helps to detect when VF sensitivity is different from that which would be expected 
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for a patent’s age. The hill of vision naturally reduces with age and as such, perimetry machines will 
require input of the age of the patient, so that it can compare against a database of correct “normal” 
values.  
Figure 1.1: The normal hill of vision. The hill is highest at fixation, where visual sensitivity is greatest. 
The height of the hill of vision declines toward the periphery as visual sensitivity diminishes. (Image 
from  Anderson DR: Perimetry with and without Automation. 2nd ed. St Louis, MO: Mosby, 1987.) 
 
While any loss of the VF may be cause for concern, there are particular patterns of loss that are 
characteristic  of glaucoma. Early glaucomatous damage is associated with either a paracentral loss, a 
nasal step, or a combination of both, in one hemifield.[25] As the disease progresses, the field loss 
becomes arcuate and then altitudinal by which time, the remaining hemifield has generally become 
affected.  
1.2.1 Short history on VF testing 
Perimetry as a method to test for visual field loss has been around for decades. The process involves 
determining if the sensitivity of the patients’ VF is different to normal, as represented in the hill of 
vision (Figure 1.1). This can be done with the horizontal approach (marking isopters using kinetic 
perimetry) or with the vertical approach (separately testing fixed locations but varying the stimulus 
luminance). Traditionally the horizontal approach using the Goldmann Bowl Perimeter was the gold 
standard. This involved the patient placing their head in a large bowl while the technician controlled an 
arm that projected a stimulus onto its surface. The operator moved the stimulus, beginning in an unseen 
region such at the periphery into a central view. The patient pressed a buzzer when the stimulus became 
visible, marking the border of their visual field at a given stimulus brightness. The operator then moves 
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the stimulus radially towards fixation to verify that the stimulus remains visible. This is generally 
repeated along each 15 degree meridian around the visual field at a fixed brightness and the location at 
which the stimulus is first seen is taken as threshold. A line joining all the threshold points is known as 
an isopter. This is then repeated using different stimulus luminances and/ or different stimulus sizes to 
form additional isopters. As the operator controlled the position and movement of the stimulus by hand, 
this is known as manual kinetic perimetry. An example of an output of this is in Figure 1.2. The vertical 
approach, known as static perimetry, where a stimulus is presented at a single position in the field of 
view was also possible on the Goldmann perimeter but was very time consuming. This process became 
much quicker with the introduction of computers, leading to automated perimetry. Software enables 
control of the stimulus parameters, such as the uniform luminance white background, the stimulus size, 
duration and location and the stimulus algorithm (strategy) for the estimation of threshold . Smart 
algorithms (such as the SITA family of algorithms discussed later) allowed for an even further reduction 
in testing time. This approach has been so successful that it is still considered the gold standard for 
visual field testing today.  
 Figure 1.2: Mock example of a Goldmann Perimetry test result. The red crosses represent one isopter 
with a high luminance and the blue crosses represent another isopter with a lower luminance. The blind 





1.2.2 Current state of VF testing 
When using perimetry to monitor or test for glaucoma, examinations are done monocularly with the 
contralateral eye being covered with an eye patch. The patient’s head is placed on the chin rest and they 
are instructed to keep their eye fixated on a single central point. White circular stimuli are then presented 
and the participant presses a button on a handheld remote when they see a presented stimulus. Different 
locations within a given region of the VF are tested until the threshold (defined below) is estimated at 
each point. The luminance of the stimuli on the Humphrey Field Analyzer (HFA) can vary between 
0.08 to 10,000 apostlibs (abs; a measure of luminosity). This is reported in decibels (dB; a unit of 
measurement to express the ratio of one value to another on a log scale) of dimming from 0 dB (the 
brightest stimulus) to 51 dB (the dimmest stimulus). The formula to calculate the decibels from apostlibs 
(A) is: 





VF tests can employ either threshold or suprathreshold algorithms. In suprathreshold perimetry the 
stimulus is presented at aa luminance brighter than the age-corrected normal value and the response is 
either “seen” or “not seen”. With this method, the depth of the any defect is unknown. Moreover, the 
suprathreshold increment is such that it can fail to detect loss which lies inside the increment.[26] 
In thresholding tests, the stimulus brightness is varied with the goal of determining the luminance at 
which there is a 50% chance of the participant seeing the stimulus. This is carried out by using a 
psychophysical technique, usually by up-and-down staircase or bracketing methods. The original 
comprehensive VF testing algorithm was known as the (Full) Threshold strategy. This general principle 
of this strategy was to start with a luminance which was either infrathreshold or suprathreshold relative 
to the expected normal value and then to present the subsequent luminance 4 dB brighter or dimmer, 
depending upon the response of the patient. Once the threshold had been crossed the direction of the 
staircase was reversed and the stimulus was presented in 2 dB steps. The threshold at any given point 
was either the mean of the last “unseen” and “seen” values or the last “seen” value depending upon the 
type of perimeter. This meant there was a resolution of 2 dB and a difference from the “true” threshold 
of around 1 dB. On the Octopus system, the order of VF points was determined randomly. With the 
HFA, one “seed” point at 9,9 degrees in each quadrant were threshold initially and the starting value 
for their adjacent points were derived from these values.[26] Another earlier algorithm of the HFA, 
known as the FASTPAC algorithm was an attempt to make VF testing even faster and is designed to 
achieve threshold in two thirds the time of Full Threshold. It uses a single crossing with a 3 dB step 
size. While quicker, there is an increase in within-test variability (short term fluctuation) and 
underestimation of focal loss in glaucoma. 
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A “smarter” family of strategies, known as the Swedish Interactive Threshold Algorithms (SITA) that 
were developed in the 1990s, use additional information to allow for more rapid analysis without trading 
off accuracy.[27]  The two versions of the SITA algorithm that are relevant to this thesis are the SITA 
Standard and SITA Fast strategies. They are designed to replace the Full Threshold and FASTPAC 
strategies respectively. These algorithms use likelihood functions for each location. A likelihood 
function measures the “goodness of fit” of a statistical model to a sample of data for given values of the 
unknown parameters. The functions are adjusted after each positive or negative response at a stimulus 
location. As the test proceeds, the height of the function estimates the most likely threshold value and 
the width measures the certainty of the estimate. SITA Standard uses a 4-2 step size like Full Threshold 
whereas SITA Fast uses a 4 dB step size. The testing stops when a specific level of accuracy is obtained, 
measured by the Error Related Factor.[28] The SITA algorithms are 50% faster than the algorithms they 
sought to replace. Depending on the eccentricity that requires testing, each algorithm examines out to 
27 degrees, 21 degrees or 10 degrees, and are named 30-2, 24-2 and 10-2 respectively. The former 
provide locations based upon a 6 degree square grid whilst the latter provides location based upon a 2 
degree square grid. The -2 refers to the fact that the locations do not lie on the horizontal or vertical 
meridians but are offset by 3 or 2 degrees. See Figure 1.3 (Section 2, left) for the grid layout on a sample 
subject. 
The SITA Standard strategy tends to take around 7 minutes per eye for Program 24-2 and the SITA Fast 
strategy, as its name might suggest, is slightly faster at around 4 minutes per eye. The SITA Fast strategy 
has been shown to slightly underestimate VF defects and so it is recommended more for screening 
purposes and the SITA Standard strategy is recommended for closer monitoring. Despite this, 
discrepancy, it has been shown that there is little difference in the time to detect glaucoma progression 
using either strategy.[29] Newer strategies are constantly being developed, even within the SITA 
family. The SITA Faster strategy, which looks to replace SITA Fast, is currently being rolled out and a 
clinical evaluation shows it to be around 30% faster with little difference in results.[30] 
The printout of the results from automated perimetry are relatively standardised between the different 
types of perimetry and an example printout can be seen in Figure 1.3. In section 1 various fields of 
information, such as patient data, information about the settings of the test (stimulus size, strategy name, 
refractive error correction etc.) as well as the reliability indices are visible. These reliability metrics, 
False Positives, False Negatives and Fixation Loss attempt to quantify how well the participant was 
complying with the testing procedure. Every time the subject presses the button when no stimulus was 
presented (false positive) or didn’t press the button when a stimulus that should be visible was presented 
(false negative), this information is recorded and presented in the printout. To attempt to control for 
fixation, a stimulus is sometimes presented to the blind spot (an area that should not be visible). If the 
participant can see this presentation and presses the button, it may mean that they were not fixating at 
the central target. Of these three reliability indices, the literature tends to show that false positives are 
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the most significant predictor of performance.[31] In Figure 1.3, Section 2 the raw pointwise sensitivity 
values (in dB) and the corresponding greyscale plot can be seen. The greyscale plot visually represents 
scotomas (area of partial visual function loss) and VF defects, with the darker areas representing regions 
with more severe VF loss (i.e. regions that are less sensitive) regions. In Figure 1.3, Section 3 the 
patients’ results compared to age-matched normative data is also visible. In the total deviation plot (top, 
left) the numbers represent how the subjects VF sensitivity differs to a healthy normal population. The 
pattern deviation plot (top, right) attempts to represent focal depressed areas when accounting for a 
blanket/diffuse reduction in sensitivity (as estimated by the total deviation plot). Conditions such as 
media opacities caused by cataracts or vitreous haemorrhages can cause an general reduction in 
sensitivity across the whole VF which is not representative of glaucomatous damage, and the pattern 
deviation plot tries to correct for this. 
Finally, but arguably most importantly, at least for the analyses described in this thesis, in Figure 1.3, 
Section 4 is where the summary metrics are. From top to bottom is the Glaucoma Hemifield Test (GHT), 
the Visual Field Index (VFI), Mean Deviation (MD) and Pattern Standard Deviation (PSD). The GHT 
compares the upper and lower hemifields for differences and then reports whether the difference is 
within normal limits, borderline or outside of normal limits (indicating possible glaucoma damage). 
The VFI outputs a percentage from 100% (indicating a perfect, age-adjusted VF) to 0% (no visual 
function). It weighs the central points more heavily than the peripheral points when calculating the 
percentage score as these are typically more useful for visual function. The MD value gives a simple, 
average difference from normal values in the subject’s age group, where a lower (more negative) score 
represents more damage. For example, a value of -8.76 dB means that the subject’s VF was an average 
of 8.76 dB lower than that from a visually healthy control across all the points. The PSD value provides 
information about localised loss, with a high value indicating a non-uniform sensitivity loss (i.e. not 
from cataracts, which could cause a largely negative (bad) MD value). While PSD in theory sounds like 
a better measure of VF worsening, it has a couple of drawbacks. Namely, the PSD value may seem to 
improve even when VF sensitivity is worsening due to it attempting to correct for global depressions. 
For this reason, most of the research in this thesis uses the MD value as a summary measure for visual 
function (although PSD is used in some chapters in conjunction with MD).  
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Figure 1.3: Example of a HFA VF printout. The printout is made up of 1) Patient information, test 
settings and reliability indices, 2) Sensitivity and greyscale printouts, 3) Total deviation and pattern 




As with any psychophysical testing, a large source of unreliability or variability (noise) comes from the 
participants themselves. Even with a young, healthy and perfectly compliant subject, the test-retest 
reliability of VF exams can be large.[32–34] One main factor that introduces unwanted variability into 
VF testing (especially over time) is a “learning effect”. A learning effect (with regards to VF testing) is 
a process in which a subject’s results may seem to be improving (their VF sensitivity increasing, for 
example) but in reality the subject is just becoming more familiar with (and better at) the testing process. 
This effect has been shown to happen over several visits. It is for this reason that often times, the first 
(or first few) VF exams of a series are excluded as they could be artificially worse due to inexperience 
with the testing process.[35,36] In this thesis, any study that deals with longitudinal data excludes the 
first VF in a participant’s series to attempt to mitigate this learning effect. A complement to the learning 
effect is a so-called fatigue effect. In many of the older (and slower) testing strategies, it was shown 
that as the duration of the test increased, the VF sensitivity tended to decrease (and variability increased) 
as patients became fatigued. Often a short break of a few minutes was not enough to combat this. Very 
little research of a fatigue effect had been done to date on the more recent (and quicker) testing strategies 
(SITA family). In Chapter 2 of this thesis, a short-term fatigue effect using the SITA strategies is 
investigated. 
In real terms, even though SAP is the gold standard of VF testing, it is far from perfect. As mentioned 
earlier, due to the subjective nature of psychophysical testing, results tend to have a lot of noise. Even 
with the most compliant patients, it can take many tests over time before a clear picture of how the VF 
is changing becomes clear. Taking the test itself can be unpleasant too, especially for older people 
(which happens to be the demographic that most frequently uses it).[37] Sitting on a stool that is 
incorrectly adjusted can be uncomfortable and staring at the fixation target can be tiresome.[37] This 
perhaps may be a thing of the past as newer forms of VF measurements become available. In recent 
years, a lot of work has been done to make VF testing less strenuous. Laptop and tablet-based tests 
(possibly suited to home testing) are being trialled as are eye tracking approaches that require no input 
from the participant.[38] It is possible that some day, the laborious act of balancing your head in a white 
dome will be a thing of the past. Until then however, SAP is a necessity as are techniques to analyse 
the data it produces. There are many groups around the world working on this problem.[39–46] 
1.2.3 Analysis of VF data 
Collecting the VF data is only one of the challenges when it comes to understanding visual function. 
Once the raw sensitivity values are collected (using for example a 24-2 SITA strategy) there are 
numerous approaches one can take to analyse the data to glean some insights from it. A common 
approach is to try to distil much the available information into one, easy to understand summary number, 
such as mean sensitivity (MS) which is just the mean of all the sensitivity values. Other slightly more 
involved metrics are more commonly used, some of which are mentioned above. Measures such as MD, 
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PSD, VFI and GHT are useful for an “at a glance” summary of the status of the eye. When only 
considering one VF exam in isolation, this is usually called single field analysis. What tends to be more 
important is how this VF changes over time. There are two main approaches to evaluate the progression 
of VF defects, event-based change analysis and trend-based analysis. 
Event-based analysis tries to answer the question, “has either glaucomatous field loss become manifest 
or has existing glaucomatous field loss worsened?”. A common example of event-based analysis 
software is the in-built guided progression analysis (GPA) included with the HFA perimeter. This 
software looks at a series of VFs over time (minimum of 3) and tries to detect if progression has 
occurred. It does this by looking at the individual pointwise pattern deviation value and checking for 
repeated consecutive significant reductions in sensitivity from the baseline value. The approach is based 
on the Early Manifest Glaucoma Trial (EMGT) criteria for VF progression. The outcomes are “possible 
progression” and “likely progression”. Possible progression is defined as three or more VF points that 
deviate beyond the 95% confidence interval for expected test-retest variability for two consecutive 
visits. Likely progression is the same criteria but for three consecutive visits. A major drawback of GPA 
is the high rate of false positives it can produce. Artes et al found that by randomly arranging 12 VF 
tests in a three month period, there was an 18.5% false-positive rate for “possible progression”.[47] 
While event-based analysis is useful for checking if a patient has progressed, it does not say anything 
about the rate of progression, or how quickly visual function is being lost over time. For this type of 
information, trend-based analyses are needed. A very simplistic trend-based analysis is to take one of 
the VF measures, and model it over time using a linear regression. The slope of the fitted line, measured 
in dB/year, gives an estimation of how much dB would be lost per year at the current rate with no 
intervention. Many of the studies in this thesis utilise this type of analysis using ordinary least squares 
(OLS) linear regression models. Linear regression can be applied to the summary metrics (such as MD 
or PSD), to clusters or to individual points. Knowing an estimate of the rate of VF loss can give an 
indication of when a patient may experience severe VF loss (or even blindness) and so is useful for 
informing a clinician of what course of treatment to take. VFI is a trend analysis that scores the VF from 
100% (normal, healthy eye) to 0% (end stage glaucoma). A linear regression of VFI over time can be 
used to measure the rate of VFI deterioration.  
The Medisoft PROGRESSOR software is frequently used in a research setting to evaluate glaucoma 
progression.[48,49] A linear regression is fitted for each test location and the slope and p-values are 
used to detect how many locations are “significantly” progressing. The criteria of an eye progressing is 
usually determined by a number of statistically significant progressing test locations. The downside of 
this approach is that confounding factors such as a diffuse media opacity (cataracts) can result in a false-
positive for glaucoma progression. 
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The above highlights that with linear regression, the progression criteria (slope and p-value of varying 
locations) is somewhat arbitrary. The permutation of pointwise linear regression (PoPLR) approach 
combines the pointwise statistics into a single statistic using the Truncated Product method and then 
calculates the p-value for overall change through permutation analysis.[50] This method is an 
individualised approach that assumes the ordering of the VF tests does not matter unless actual VF 
deterioration has taken place. It is independent of factors such as baseline VF damage, number of test 
locations, length of follow-up and dB scale making it useful to compare VF progression across different 
types of protocols.  
Other more sophisticated models exist that can be used to model VF progression. Multi-level models 
are statistical models that vary on more than one level. For example, a model of a patient that contains 
measures for individual patients as well as the clinics they attend. They are extensions of linear models 
that are useful for dealing with “nested” data. When using this type of model, researchers must decide 
what parameters will be included in the model and whether they will be “fixed” or “random”. Fixed 
effects are constant across groups whereas random effects can be different across groups. These types 
of models are also known as mixed-effects models as they can contain both fixed and random effects. 
In the context of modelling VF progression over time, there are two main variables that a researcher 
must be concerned with, they are the intercept and slope. The slope is the rate of progression over time 
(dB/year) and the intercept is the MD value at time zero (baseline). These two criteria can be fixed or 
random across groups. It’s possible to have a model where slopes are modelled as fixed but intercepts 
are modelled as random. In the above example, this model would assume that the rate of VF progression 
is the same across the clinics and that only presentation (intercept) can vary. The most realistic (but 
most complex) models are usually when the slopes and intercepts (and other possible variables) are 
modelled as random. Increasing complexity does not always provide a better model and so there are 
model fit statistics available to judge how well the model balances complexity and accuracy. These 
include the chi-square likelihood-ratio rest which can be used to build/compare nested models, and the 
Akaike or Bayesian information criteria (AIC and BIC respectively). There are many more types of 
perimetry and many things that need to be considered when analysing VF data that are not listed here. 
To find out more about recent developments in perimetric testing and analysis, the reviews by Wu and 







1.3.1 Electronic Medical Records  
Once the various examinations are administered and treatments are prescribed, it is useful to have these 
data stored somewhere for easy patient management. Historically this has been done manually using 
paper records, with electronic tests being stored on individual machines. A more efficient solution to 
this was the Electronic Medical Record (EMR) system. These EMRs are computer-based record 
keeping systems that have the long-term aim of replacing paper records within medicine. Traditional 
paper medical records would be replaced with structured, digital data stores which could be easily 
searched for, exported and analysed. The interested reader can find out more about using EMRs in 
health outcomes research in the review by Dean et al.[53] An ideal EMR would be connected to the 
various instruments in a clinics and any examinations could be easily (or automatically) added to the 
patients’ records. If set up and utilised correctly, a clinician would have full access to any and all patient 
information or results from a single computer. An example view of the Medisoft EMR is shown in 
Figure 1.4. These EMRs have been introduced into many ophthalmology clinics and studies 
investigating their impact are beginning to emerge.[54–67] 
Across the UK, EMR systems are slowly being rolled out to healthcare providers. There were plans for 
the National Health Service (NHS) to go fully digital by 2020 although for a variety of reasons this has 
not been achieved.[68] One reason for the delay is a lack of funding support. Another may be a lack of 
clinical engagement. In 2002, The National Programme for Information Technology (NPfIT) was a 
£12.4 billion initiative to revamp the English NHS with IT. Despite some successes, it was discontinued 
in 2011 and dubbed a “fiasco” in the media. The main consensus for this was that without the 
involvement of clinics, the focus was on merely getting computer systems into the NHS and not on 
service change. Clinicians were forced to adapt to these changes without being given reasons for why 
they were happening and without any strategy for engagement.[69]  
While the introduction of computer systems to hospitals has been fraught with issues, GP practices in 
England are almost completely digital, working with some form of EMR system. The benefits of these 
systems are numerous but a few that have been cited are: less space required for paper notes, helpful 
and customisable decision support programmes and improved quality of care demonstrated by less 
errors, reduced variability and the ability to easily compare practices.[70] A number of drawbacks 
include a lack of training and user interfaces that are cumbersome and inflexible. There is a whole field 
of research around user interfaces (UX design) and finding out the best approaches for getting users to 
use software appropriately.[71–73] It is not always the case that the users know best. What users might 
prefer (free text boxes for notes, drop down menus) or what may be familiar to them, in all likelihood 
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will not be the most efficient way to do things. Striking a balance between ease of use and efficient use 
will be the main factor that holds back EMR uptake. 
In an ideal world, all aspects of healthcare would be digitised and available for all those involved in 
health service delivery. The possibilities for further integration are numerous. If general practitioners 
and pharmacies were added to an EMR network, it could streamline the prescription of drugs as well as 
recording a more thorough medical history.[74,75] 
Figure 1.4: Example view of an EMR system entry (image sourced from the Medisoft Medisight 
website. The data is not from a real patient.) 
 
1.3.2 Using VF data to help in glaucoma management 
SAP is widely used in research settings but is possibly underutilised within clinical practice.[76] As 
IOP is the only modifiable risk factor for disease progression, it becomes the centre of attention in the 
follow-up and management of glaucoma patients. While recommendations state that new glaucoma 
patients should receive 6 VF tests within the first two years of diagnosis, this is often not met.[6] A 
clinical audit of glaucoma clinics in England found that most newly-diagnosed patients received less 
than three VF tests within in the first two years. [77] Many of the sophisticated methods to analyse VF 
defects mentioned previously are not available to the clinician and so they must rely on pre-packaged 
software such as the GPA on the HFA. This is slowly changing as EMR systems that have 
ophthalmology packages are being introduced into practices. Control of IOP is usually the main factor 
in deciding treatment adequacy. This over-reliance on IOP may contribute to glaucoma patients 
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becoming visually impaired or blind while under care.[78,79] If the goal of treatment is to preserve 
visual function and prevent visual disability, then the measures of function must be given equal if not 
more consideration than IOP. As POAG can present with normal (low) IOP in the form of NTG, it 
does not make sense to measure adequacy of treatment with a measure that is not necessary nor 
sufficient in glaucoma.  
The possible reasons for underuse of VF testing are numerous. SAP generates large volumes of data 
that can be time consuming to collect and even more so to interpret without adequate software. 
Patients, too, are not fond of the procedure but accept that it is a part of their routine care.[23] Despite 
this, having sufficient VF data and analysis methods are crucial in providing the clinician with the 
tools that are needed to provide more targeted care and better functional outcomes. Results from a 
study looking at the frequency of VF testing in the UK found that increased early testing may in fact 
be cost-effective. This is even more so when gains to society rather than just the NHS are considered. 
[23] Despite this, many glaucoma specialists consider increased surveillance of the VF would be 
impossible with current resources.  
Functional testing, particularly binocular testing, is the best approximation as to how disease will 
affect daily life. This makes it all the more important to put in place measures to make use of as much 
VF data as possible. Smart EMR systems that can incorporate decision support algorithms could 
improve clinical management. The introduction of newer/improved VF analysis could make better use 
of the limited resources glaucoma clinics possess. If increased VF testing would be impossible within 
clinics, perhaps at-home monitoring could play a role in future glaucoma management.[38] If these at-
home tests were able to connect to a hospitals EMR, it could free up time and resources for clinic 
visits.    
1.3.3 Data used in this thesis 
The two sources of patient data used for the studies in this thesis both come from EMR extractions of 
glaucoma clinics in England. Both of the datasets were collated and stored on Medisoft (Medisoft Ltd., 
Leeds, UK) EMR systems. 
The first of these, the VF only dataset, contains 473,252 VFs from 88,954 patients extracted from three 
different glaucoma centres in England. These are Cheltenham General Hospital Gloucestershire (2000-
2011), Queen Alexandra Hospital in Portsmouth (1999-2011) and the Calderdale and Huddersfield 
NHS Foundation Trust (2000-2011). Data access was granted by the Caldicott Guardians (person 
responsible for protecting the confidentiality of peoples healthcare information in hospitals in England) 
at each centre. As well as the usual data that is recorded on a HFA (date of birth, time of test, VF results 
etc.) it also contains patient postcode data. This dataset has previously been used by others to explore 
aspects of VF testing including measurement precision, frequency of testing and health economic 
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factors related to glaucoma.[23,34,77,80–84] The data was used in various studies investigating the 
health economics of glaucoma, the variability of perimetric testing and the use of perimetry in the fitness 
to drive test. This dataset is used in Chapters 2 and 6 of this thesis to investigate additional aspects of 
VF testing. While many interesting studies can be designed using the data contained in this dataset (VF 
data plus additional postcode data), it would be also useful to know more about the subjects. If this 
dataset could be linked to other related datasets (such as one containing medications or IOP 
measurements) it would greatly increase the range of studies possible. 
The second dataset used in this thesis, contains data from several linked sources. As well as VF test 
records, there are records of patient demographics, history of diagnoses, medications, IOP 
measurements, visual acuity records, recorded co-pathologies and glaucoma surgeries. There are also 
records of cataract surgeries and diabetes status. The data were extracted from Gloucestershire Hospitals 
NHS Foundation Trust, Hinchingbrooke Health Care NHS Trust, Peterborough and Stamford Hospitals 
NGS Trust, Portsmouth Hospitals NHS Trust and the University Hospitals Bristol NHS Foundation 
Trust. These data were recorded between April 2000 and March 2015. The National Ophthalmology 
Database (NOD) was established under the auspices of the Royal College of Ophthalmologists 
(RCOphth) in 2010. The NOD aimed to collate pseudonymised data collected as a by-product of routine 
clinical care using EMR systems for the purposes of national audit, research and establishing 
meaningful measures for revalidation of ophthalmologists.[85] In 2014, the Healthcare Quality 
Improvement Partnership (HQIP) commissioned NOD to do a feasibility study to investigate the use of 
VF data to audit activity in glaucoma clinics. The results of the study are reported in Chapter 3, with 
the specific aim of examining the viability of extracting meaningful metrics of health service delivery 
that might in future allow comparison between glaucoma clinics. A further look at the other research 
outputs from NOD are also discussed in Chapter 3. A data sharing agreement between NOD and City, 
University of London was established to allow additional future studies relating to various aspects of 
glaucoma management in the hospital eye services. The work generated from these studies appear in 
Chapters 3 to 5. 
Supplementary data from various sources are also used in the studies contained in this thesis. Statistics 
from the UK government Office of National Statistics (ONS) on socioeconomic deprivation were 
sourced from the GOV UK website (https://data.gov.uk/dataset/8f601edb-6974-417e-9c9d-
85832dd2bbf2/english-indices-of-deprivation-2015-lsoa-level). Census data relating to the age and 
ethnicity of populations in parts of England were also sourced from the GOV UK website 
(https://data.gov.uk/dataset/150b43db-10ce-465d-9961-29e679350a9d/2011-census). Additional data 
such as shapefiles (the files used to store mapping data) and location of optometrists (used to draw the 




The prime objective of Big Data analysis is to process data of high volume, velocity, variety and veracity 
using traditional and novel computational techniques.[86] According to IBM, 90% of the data that exists 
in the world today was created in the last two years. This data is coming from all sorts of sources, from 
YouTube videos to social media updates and now increasingly, medical data. At this rate of growth, a 
proper understanding of how to manage electronic medical Big Data will be crucial to extracting useful 
insights in the future. The main aim of this thesis is to determine what can be done with regards to 
analysing existing large databases of routinely collected ophthalmic data. Chapters 2 through 6 are a 
selection of studies that show the broad range of research that can be carried out using data available in 
glaucoma clinics. They highlight the current opportunities in ophthalmic research, specifically gaining 
insights about glaucoma testing, the progression of ocular hypertension, how glaucoma is affected by 
uveitis and the relationship between glaucoma and socioeconomic status using Big Data. As well as 
opportunities, this thesis also involves highlighting where data-related challenges had to be overcome 
to achieve these results.  
Chapter 2 answers the question of whether there is a clinically meaningful difference in the results of 
the first and second eyes tested with SAP. Often if there is a real effect, no matter how small, an 
increasing amount of data will eventually produce a statistically significant result. If the effect is too 
small however, it may not be clinically relevant. This chapter highlights the difference between a highly 
significant result (due to the sheer amount of data) and usefulness in clinic. 
The remaining chapters (3 to 6) use a second dataset in their analyses. This dataset comes from multiple 
sources and is linked together using the anonymised patient ID. With additional demographic 
information it is possible to analyse the large volume of data from each clinic and compare them to each 
other. Chapter 3 compares five English glaucoma clinics based on selected VF (severity, reliability and 
frequency), demographic (age, gender) and mixed (predicted loss of sight years) metrics. The amount 
of data from clinics is drastically increasing and smart management of these data is crucial to be able to 
identify its utility. In Chapter 4, VF data is linked with diagnostic, demographic, IOP, surgical, 
medication and comorbidity data to predict the in-clinic conversion rate from OHT to visual field loss. 
The real world is quite different to clinical trials and it is not a guarantee that results from trials are 
easily transferable to a clinic setting. This study combines various different sources of data to model 
OHT conversion and compares it with prominent trial results to determine if there is a difference. 
Chapter 5 looks at a subset of patients with both uveitis and glaucoma. As this a relatively rare 
combination within glaucoma clinics, a population size of almost 100,000 is needed to find 200 patients 
fitting the inclusion criteria. This study emphasises the power of using Big Data to carry out studies on 
rarer conditions or combinations of conditions. In Chapter 6, socioeconomic and VF data are linked to 
investigate the association between deprivation and glaucoma presentation and progression. Other 
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studies have shown a link between socioeconomic deprivation and late glaucoma presentation but this 
study highlights that once these patients are monitored within the health service, they have similar 
outcomes to affluent populations.  
Finally, Chapter 7 provides a brief summary of the key findings from the previous studies and discusses 
them in the context of past and potential future work. The findings will be disseminated to glaucoma 
care providers and policy makers through direct and indirect channels.  
The works contained in this thesis have been presented at national and international conferences by 
myself and colleagues and have been positively received. Many of the contacts made during the course 
of this PhD have been with academics who sit on scientific committees or are a part of groups/charities 
that campaign for policy change. It is my hope that these works can affect some positive change for 
those who are afflicted by glaucoma.   
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Dataset 1 primer – The visual field dataset 
 
The data used in Chapter 2 is an extraction of VF data (along with postcode data) from several glaucoma 
clinics across England. Medisoft VF databases (Medisoft Ltd., Leeds, UK) containing 473,252 VFs 
from 88,954 patients were extracted in 2012 from glaucoma clinics at Moorfields Eye Hospital in 
London; Cheltenham General Hospital Gloucestershire Eye Unit; Queen Alexandra Hospital in 
Portsmouth and the Calderdale and Huddersfield NHS Foundation Trust [81,84,87]. Data access was 
granted by the Caldicott Guardians (person responsible for protecting the confidentiality of people’s 
healthcare information in hospitals in England) at each centre. The data was anonymised at the point of 
extraction, so that no identifying information was transferred to City, University of London. The data 
was transferred via encrypted flash storage to the secure City, University of London database. Access 
is restricted to only those that possess an account that is flagged for access. The studies using these data 
adhered to the Declaration of Helsinki and all analyses of the data were approved by a research ethics 
committee of City, University of London. 
These data have previously been used in several studies investing various aspects of glaucoma and VF 
progression. Saunders et al. published several studies using these data revolving around the precision 
of measurement of VF testing, the relationship between MD and the legal fitness to drive and predicting 
VF loss of patients based on their remaining lifetime.[29,82,87,88] Boodhna et al. published two 
longitudinal studies investigating the change in trends in glaucoma clinics over time.[81,84] Russell et 
al. used the data to investigate the variability and sensitivity of VF testing.[34,89] 
One limitation of using this type of data is the lack of diagnosis labelling for patients. Although they 
are in glaucoma clinics and receiving VF testing, many patients may only be there for a once off test or 
for a false positive referral. As such, if one is trying to develop a surrogate label of patients with POAG, 
additional criterial, such as a minimum number of visits would be needed. In Chapter 2 date and time 





2 Does the eye testing order for visual fields matter?  
The work presented in this chapter has formed a paper published in Acta Ophthalmologica (Kelly et al., 
2019); see list of supporting publications. The co-authors on this paper are Susan Bryan (SB) and David 
Crabb (DC). The analysis contained in the study (including the R code and production of figures) and 
the drafting of the manuscript was carried out by SRK which was reviewed and edited by SB and DC. 
This work was presented at the Association for Research in Vision and Ophthalmology 2018 
conference. 
2.1 Introduction 
The primary method for determining functional deterioration in glaucoma is an evaluation of VF series 
over time, as measured by standard automated perimetry (SAP). Examination results from SAP are 
susceptible to high levels of measurement variability from different sources, including the patient 
themselves. Good examination procedures and instructions produce usable results in the vast majority 
of patients.[6,90] Nevertheless, measurement variability in SAP hampers clinical interpretation of the 
VF. For example, several examinations need to be considered before progression or stability of the VF 
can be confirmed with confidence against this background of measurement variability.[6,91] 
The fatigue effect mentioned in Chapter 1 has been shown in studies to also exist within a single session 
of perimetry, decreasing sensitivity in the second eye tested.[92,93] Studies reporting these effects were 
conducted at a time before better perimetry algorithms were developed to reduce test time. More 
efficient examination techniques, like the Swedish Interactive Testing Algorithms (SITA Standard or 
SITA Fast) on the Humphrey Field Analyzer (HFA; Carl Zeiss Meditec, Dublin, CA), have become a 
clinical standard and are assumed to be less susceptible to fatigue effects.[80,94,95] 
SAP necessitates testing both eyes separately and sequentially. Conventionally, the right eye is usually 
tested first so that any examination order effects will be as constant as possible from visit to visit. Few 
studies have considered this testing order effect in SITA testing. One study examined patients with two 
prior sets of SITA Standard 24-2 test results performed on the right eye first.[96] A subsequent test was 
performed on the left eye first. No significant differences in summary measures of the VF were found 
suggesting that, on average, it probably does not matter which eye is tested first. These findings might 
be corroborated by comparing right eye with left eye perimetry results among a large number of patients 
whose right eyes had been tested first. This is an idea examined in this study. If the VF sensitivity in 
the second tested (left) eye is worse than in the first tested (right) eye then this may suggest a testing 
order effect. Measurement variability from fatigue effects in the second tested eye may also possibly 
accumulate over a series of follow-up visits; this is also explored.  
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This study investigates an eye testing order effect in retrospectively observed large-scale VF data from 
glaucoma clinics. First, the hypothesis that average VF sensitivity is worse in the second tested (left) 
eye compared to the first tested (right) eye in HFA SITA VFs is tested. Second, a surrogate of 
measurement variability in the second tested (left) eye compared to the first tested (right) eye in series 
of HFA SITA VFs is examined. Furthermore, to what extent any detectable order effect is associated 
with patient age and the length of rest time between first and second eye examinations is analysed. As 
measurement variability is inherently linked to the number of VFs required to estimate the likelihood 
of progression, these findings could help determine if detection is being delayed due to a second-eye 
fatigue effect. 
2.2 Materials and Methods 
As mentioned in the VF dataset 1 primer, this data uses a multi-centre Medisoft VF dataset. No other 
clinical data was made available other than each patient’s age. Subsequent analyses of the data were 
approved by a research ethics committee of City, University of London and this study adhered to the 
Declaration of Helsinki. 
Patients aged 30 years or older with VFs from the HFA using Goldmann size III (white-on-white) 
stimuli with the 24-2 test pattern acquired with either SITA Standard or SITA Fast testing algorithms 
were included in the study. Patients were only included if they had at least six recorded VF examinations 
(consistently with SITA Fast or consistently with SITA Standard) where both eyes were tested on the 
same day. Patients were not excluded on the basis of longer follow-ups but for these analyses, only the 
first six examinations were considered. The first VF in each series was then omitted in order to attempt 
to account for perimetric learning effects.[97,98] This left a total of 6,901 patients for analysis. These 
data represent a population of people receiving routine follow-up in glaucoma clinics in England. 
For these analyses, only patients where eyes were tested in the same order at each examination, with 
right eye tested first, were included. The first VF examination of each series was defined as the baseline 
VF. HFA mean deviation (MD) values were extracted for each VF for each eye. MD estimates overall 
VF sensitivity, relative to healthy age-matched observers, with more negative values indicating greater 
VF sensitivity reduction. Average MD for first eye tested (right) and second eye (left) tested, from the 
baseline examinations only, were compared; no difference in these values would suggest no average 
systematic eye testing order effect. 
To investigate differences in long-term measurement variability in the eye tested first or second, MD 
over the five examinations was analysed for each patient. Ordinary least-squares linear regression of 
MD against time was used to extract errors (predicted values minus the observed sensitivity [dB] values) 
at each examination (Figure 2.1). The mean of these absolute errors (MAE) was used as the estimate of 
long-term measurement variability. For example, a series exhibiting high measurement variability 
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would have variable MD values (after removing any trend for change over time) yielding a high MAE 
value. The increase (or decrease) in MAE for the second tested eye compared to the first tested eye, 
relative to the average MAE in both eyes, was calculated; this effect, expressed as a percentage, was 
the surrogate used for long-term measurement variability due to an eye testing order effect (See Figure 
2.1). VF measurement variability is directly related to the amount of VF loss.[89] For example, a patient 
with early VF loss in their first tested eye but advanced loss in their second tested eye will likely have 
more measurement variability in the latter regardless of any fatigue effects. Therefore, in order to 
minimise noise the analyses were repeated on a subset of patients where overall VF loss was similar in 
both eyes (left and right eye baseline MD within 3 dB of each other).  
Furthermore, it was also examined if this potential order effect was associated with the age of a patient 
or the rest time between the first and second eye exam. All analyses were done using R (R Development 
Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical 
Computing, Vienna, Austria, URL: http://www.R-project.org, 2008). 
Figure 2.1: Calculation of absolute errors (vertical lines) and relative MAE increase (%) for two 
different patients. Patient 6013 has more long‐term measurement variability in the second eye tested 
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with a 45% increase in the surrogate measure. In patient 6002, the long‐term variability is more similar 
in both eyes. 
 
2.3 Results: 
Median (interquartile range [IQR]) age of the patients and length of follow-up for the five examinations 
was 66 (56, 73) and 4.5 (3.5, 5.8) years respectively. From the population of 6,901 patients with 
sufficient VF follow-up, 6,320 (91.6%) had consistently been examined in a right eye then left eye 
sequence at each SAP examination. Only seven (0.1%) patients had been consistently examined in left 
then right eye sequence. The remaining patients (574; 8.3%) were excluded due to the eye testing order 
not being consistent (not always right eye first). These numbers illustrate the remarkable adherence to 
the convention of testing the right eye first in perimetric examination in the clinic. 
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Figure 2.2: Distribution of the percentage change in second eye variability with labelled median and 
10th, 25th, 75th and 90th percentiles. 
 
Median (IQR) MD in the first tested (right) eye and second tested (left) eye was -2.57 (-6.15, -0.58) dB 
and -2.70 (-6.34, -0.80) dB respectively. This average decrease in MD from first to second tested eye 
was statistically significant (Wilcoxon signed rank test; p<0.001) but small in magnitude (median 
difference of 0.13 dB, 95% CI: -0.26, -0.02). This average worsening in VF sensitivity in the second 
eye tested could be explained by a fatigue effect but the magnitude of the average effect is small.  
Measurement variability in MD values from series of VFs performed in clinics, as measured by relative 
change in MAE, varies considerably between eyes in the same patient (Figure 2.2). Relative median 
(IQR) increase in second tested (left) eye measurement variability (order effect) was 3% (-43, 50%) and 
this was statistically significant (p<0.001). This effect was small and obviously not consistent across all 
patients. Yet, it does indicate that on average the second tested eye in SAP accumulates slightly more 
measurement variability during a follow-up in a routine clinic. This average effect remained unchanged 
(median = 3%) when  analysis is restricted to patients with similar overall VF loss in both eyes 
(n=4,528). Yet, as would be expected, the IQR narrowed, but only moderately (-39, 48%). The analysis 
was also repeated using series of 10 VFs, the IQR narrowed again to (-30, 33%).The eye testing order 
measurement variability effect was not associated with the age of a patient (p=0.20), nor was it 
associated with the time (seconds) between testing the first and second eye (p=0.53) with R^2 ~ 0 in 
both cases. (Figure 2.3). So, any accumulative measurement variability in the second tested eye is not 
inflated in older patients or associated with the period between each eye examination.   
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Figure 2.3: Scatter plots showing the change in variability as a function of baseline age (left) and rest 
time between exams (right) with fitted linear model (blue). The blue line would slope upwards (or 
downwards) to indicate a change in effect size with age or rest time. The time between tests is censored 
at 600 seconds resulting in 0.3% of patients being excluded. 
 
2.4 Discussion: 
Several factors contribute to measurement variability in automated perimetry. For some patients this 
perimetric variability may be inflated by examination fatigue, which will worsen during prolonged 
testing. Therefore, the second eye examined may be more susceptible to fatigue induced variability. 
This leads to at least two scenarios in the clinic: an instruction to examine the eye of interest first or 
examining eyes in a consistent order so that any fatigue effects will be as constant as possible from visit 
to visit.  More simply, the right eye is always tested first following a convention for most eye 
examinations; this was supported by the results from this study with over 90% of patients consistently 
being tested right eye first.  
The  results of this study indicate that average VF sensitivity, as estimated by HFA MD, was slightly 
worse in the second eye examined (left eye) in a large sample of over 6,000 people. Assuming no 
physiological reason for left-right eye VF sensitivity differences this sensitivity decline might be 
attributed to a fatigue effect. This study also explored the accumulation of measurement variability in 
the second eye tested using a novel serial analysis of MD variability. Results from this analysis suggests 
some evidence of more measurement variability in the second eye tested. It is important to note this 
order effect is an ‘average’ effect and likely too small (3% increase) to impact on results from routine 
clinics. For example, it has been suggested that a decrease in longitudinal variability of about 20% is 
needed to detect a progression one visit earlier using linear regression of sensitivity values over 
time.[99] Still, in situations where small differences in average precision could affect the statistical 
power to detect an outcome measure, such as in a group of participants in a clinical trial, it might be 
worthwhile to test the “study eye” first. 
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Most studies highlighting perimetric fatigue were done when automated perimetry was hampered by 
longer exam times.[92,93,100] SITA strategies halved testing times compared to the full threshold 
algorithms and have become the standard for HFA examinations.[27,94,101,102] One study, with a 
similar aim to ours, recruited patients from clinics with two prior sets of SITA Standard 24-2 test results 
performed on the right eye first and then deliberately examined them once with the left eye first. There 
was no statistically significant difference in the MD, or the test reliability measures, among the three 
test results for either eye. The results in this study contradict these findings. It is however important to 
reiterate that the average sensitivity decline between first and second eye tested is very small and it 
probably still does not matter which eye is tested first when considering MD. A series of factors thought 
to influence SITA HFA VF measurement variability, or spurious changes in VF sensitivity, were 
thoroughly investigated by Montolio et al.[31] Not-so-obvious factors such as the time of day and the 
season (time of year) when examinations are performed were considered. The effects were real and 
statistically significant but similar in small magnitude to the eye examination order effect on 
longitudinal variability that was observed. Fatigue in the second eye tested, then, does slightly increase 
measurement variability in that eye during follow-up but in context of other minor factors, it is relatively 
similar.[31,103–105] Ultimately, to minimise VF variability patients should be encouraged to produce 
reliable results by making sure they understand what to expect, and what they need to do during an 
examination, even if they have done them several times before.[6,37,90] 
No association was found between change in between eye measurement variability (order effect) against 
age of patient, or against the rest period between right and left eye examination. These results indicate 
that older age or a shorter rest period between examinations did not explain any of the increase in 
between eye variability. Whilst the latter is interesting, interpretability is very limited by the 
retrospective nature of this data. For example, decisions about how long to ‘rest’ patients between 
examinations may be made because the patient is already tiring, complaining or asking for a rest. In 
Frequency Doubling Technology (FDT) perimetry, an experiment showed the existence of a “second 
eye” effect, where there was reduced sensitivity in the eye tested second (compared to a monocular 
baseline) when using an opaque eye-patch. This effect was abolished when a translucent patch was 
used, showing the changes were less to do with fatigue and more to do with adaptation.[110,111] 
This study was multi-centre and utilised a Big Data approach to the analysis by incorporating 
anonymised data from several thousands of patients. Using a large repository of electronically stored 
VF data is useful for auditing different aspects of glaucoma related healthcare such as testing hypotheses 
about the management of patients. Moreover, these data represent unselected people in glaucoma clinics 
that are receiving routine care and therefore estimates are directly meaningful to in-clinic or ‘real-world’ 
practice. When using Big Data it is important to be able to differentiate between statistically significant 
and clinically meaningful outcomes. This study highlights a highly significant, but very small, relative 
change in sensitivity between the first and second eye tested. The distinction is important to note 
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because as larger and larger datasets become available to use for medical research, statistical 
significance will become easy to reach. The importance in results then becomes the clinical utility and 
not just a measure of significance.  
This study has some key limitations. The dataset used in this study is missing the false positives 
reliability indices due to an unknown (and likely input ) error in handling the data before it was 
transferred. Poor practices around data storage and transfer can result in missing or corrupted data. In 
these instances, it is important to evaluate whether or not the omission of these data introduces bias into 
the study.[112] In this instance, while it may have been of interest to carry out a secondary analysis 
looking at the unreliability indices such as FP, there is evidence to show that the metrics themselves are 
unreliable. [6,107,113] As datasets become larger and sourced from multiple locations, these types are 
errors could become more frequent if proper data management practices are not maintained.   
Another limitation is that the study only considers data retrospectively. As such, there was no control 
over the data used for assessing change in long-term variability; for example, some patients might have 
deliberately not been followed with VFs in these clinics because they fatigued so badly during the 
testing. These people would not be represented in this study.   
The order effect we detected is an average effect and it varies enormously between patients. A 
suggestion for future work would be to design a study that can help determine how well a particular 
patient can remain vigilant and avoid fatigue. Clinics certainly need better ways of determining which 
individuals are more likely to produce reliable perimetric results so we can better use perimetry 
resources.[114] Better use of  eye tracking to measure surrogates of vigilance, like pupil diameter, might 
better estimate fatigue during perimetry.[115] Moreover, occlusion of one eye while testing the first 
could also affect variability in the second tested eye in perimetry in some people. This might be the 
result of perceptual deprivation (ganzfeld) effects whilst the eye is occluded.[116] It would need a 
prospective study to study this hypothesis.  
In conclusion, statistically significant average perimetric fatigue effects were observed in the second 
eye tested in routine clinics using HFA SITA examinations. However, the effects were very small and 
there was enormous variation meaning some patients may experience a perimetric fatigue effect by the 
time their second eye is examined, whilst others are unaffected. Clinically it therefore seems reasonable 
to continue to start with a right eye examination so that any perimetric fatigue effects, if they exists in 
an individual, will be as constant as possible from visit to visit. Perhaps, in situations where 
measurement precision needs to be maximised, such as in a clinical trial using VF measures as an 





Dataset 2 primer - New opportunities and challenges using linked 
datasets 
Anonymised recorded data between April 2000 to March 2015 were extracted from the Medisoft 
(Medisoft Ltd., Leeds, UK) EMR from five regionally different NHS trusts in England and linked to 
the Royal College of Ophthalmologists’ (RCOphth) National Ophthalmology Database (NOD).[113] 
These centres were Gloucestershire Hospitals NHS Foundation Trust, Hinchingbrooke Health Centre 
NHS Trust, Peterborough and Stamford Hospitals NHS Trust, Portsmouth Hospitals NHS Trust and 
University Hospitals Bristol NHS Foundation trust. 
The NOD was established under the auspices of the RCOphth in 2010. The NOD aimed to collate 
pseudonymised data collected as a by-product of routine clinical care using EMR systems for the 
purposes of national audit, research and establishing meaningful measures for revalidation of 
ophthalmologists.[85] In 2014, the Healthcare Quality Improvement Partnership (HQIP) commissioned 
NOD to do a feasibility study to investigate the use VF data to audit activity in glaucoma clinics. The 
results of the study are reported here with the specific aim of examining the viability of extracting 
meaningful metrics of health service delivery that might in the future allow comparison between 
glaucoma clinics. The resulting database contained records from 71,404 patients. As with Dataset 1, 
Dataset 2 was anonymised at the time of extraction/collation by NOD before being shared with City, 
University of London. The dataset was transferred to City via encrypted flash storage before being 
added to the secure database that is password protected. 
The database contains linked medical and demographic data such as diagnosis labelling, medications, 
glaucoma surgeries, IOP measurements, copathologies, cataract surgeries as well as information on 
diabetes status, retinal detachments and race/age/sex. This data also included socioeconomic 
deprivation scores as measured by the Index of Multiple Deprivations (IMD). While the breadth of the 
dataset is impressive, it could also pose a challenge if scaled up to more than a few clinics. As each visit 
for each patient is potentially another entry in each of the datasets, the amount of data balloons rapidly 
with for each patient. The amount and complexity of data being collected is increasing with time and 
how this will affect hospital record systems needs to be considered. Many hospitals use computers and 
servers that were not designed to handle Big Data. This could potentially lead to a slowdown (and 
potential crashing) of computer systems if not dealt with appropriately. 
This dataset is used for studies in the following four chapters. In Chapter 3 and Chapter 6, only the VF 
data and VF data plus socioeconomic data (IMD score) were used respectively. In Chapter 4, linked 
diagnostic labels are used to define three groups (POAG, OHT and Glaucoma suspect). Copathology 
data and visual acuity (VA) data were used to include or exclude patients. Treatment status (IOP 
lowering treatment or surgery) was used to classify patients into different arms for a survival analysis. 
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In Chapter 5, diagnosis and copatholgy labels were used to define the two study groups (POAG and 
POAG plus uveitis). The linked IOP records were used to investigate the relationship between IOP and 
VF progression within the two groups. A further look at some of the other studies produced using the 





3 Using electronic medical records to audit service delivery in 
glaucoma clinics 
The work presented in this chapter has formed a paper published in BMJ Open Ophthalmology (Kelly 
et al., 2019); see list of supporting publications. The co-authors on this paper are Susan Bryan (SB), 
John Sparrow (JS) and David Crab (DC). The entire content of analysis contained in the study (such as 
the R code and the production of figures 3.1, 3.2 and 3.2) and the drafting of the manuscript was carried 
out by SRK. The code for Figure 3.4 (the hedgehog plot) was produced by SB. The draft manuscript 
was subsequently reviewed and edited by SB, JS and DC. 
3.1 Introduction 
EMRs have potential to form a repository of data on patient encounters that can be directly used in 
research and clinical audit.[60] The latter can be used as a first step towards improving health service 
delivery and improving patient care. Indeed, it is only possible to gauge improvements in a process after 
it has been measured in the first place.   
Glaucoma clinics in Hospital Eye Services (HES) in England handle more than one million patient 
visits per year.[4,110] Most of these visits are for monitoring people with established glaucoma. Once 
diagnosed, all patients with glaucoma require lifelong monitoring so that any worsening of disease can 
be detected and treatment intensified accordingly. Patient management focuses on monitoring the VF, 
assessment of the optic nerve and measurement of the IOP. The latter is critical because it is the only 
modifiable risk factor for the condition worsening (progression).[7] Research evidence from clinics in 
England suggest measures of IOP are the main determinant of how often a patient is monitored over a 
period of time.[23,77] In contrast to IOP, a measurement of the VF is the closest surrogate to what 
matters to the patient in the glaucoma clinic, that is, preservation of their vision.[76] VF monitoring is 
therefore recognised to be critically important for the clinical management of the patient but it is also 
perceived to be difficult to do unless it is well implemented.[6,37,114] The computerised technology 
used to measure VFs (standard automated perimetry; SAP) has been in clinics for 20-30 years and has 
remained largely unchanged. Data from SAP are stored electronically, often in an EMR. These records, 
which are likely to be historically rich, should be amenable to easy electronic auditing. Therefore, at 
different clinical centres it might be possible, for example, to audit measures of disease severity (VF 
loss) of patients at diagnosis. Moreover, it might be possible to audit speed at which patients in different 
clinics might be losing vison and, for example, whether frequency of VF monitoring is consistent across 
clinics. It is these ideas that are explored in this report. Additional information regarding the source of 
the data can be found in the preceding primer for Dataset 2. 
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The “hedgehog plot” (Figure 3.4) is a novel approach by Bryan et al. of assessing and visualising VF 
progression within populations, in this case, in glaucoma clinics. It allows clinics or even individual 
clinicians to analyse their data easily.[115] It can also be used to swap between population level and 
individual patient level to see individual rates of progression or “loss of sight years” (a metric to estimate 
loss of vision in a person’s remaining lifetime). An online web app to visualise your own data can be 
found at https://crabblab.shinyapps.io/hedgehog. 
3.2 Methods 
The VF data were extracted from the Medisoft EMR system (Medisoft Ltd., Leeds, UK) from five 
regionally different National Health Service (NHS) Hospital Trust glaucoma clinics in England. The 
extraction was done in November 2015 and data transferred to the RCOphth NOD. All patient data 
were anonymised and subsequently transferred to a single secure database held at City university. For 
the purpose of this report the five centres are anonymised.  No other clinical data were used in this study 
other than the patient’s age, gender and the dates of the VF examinations. Subsequent analyses of the 
data were approved by a research ethics committee of City, University of London; the study adhered to 
the Declaration of Helsinki and the General Data Protection Regulation of the European Union. The 
database material contained 602,439 separate VF records from 73,994 people (Table 3.1) recorded 
between April 2000 and March 2015.  
Table 3.1: Total number of VFs per centre. Each centre is simply labelled 1-5 and represented by a 
specific colour. This colour coding is used throughout this report. (Every centre had data recorded 
between April 2000 and March 2015 except from centre 5 where data were first recorded in May 2000) 
 Centre 1 Centre 2 Centre 3 Centre 4 Centre 5 
Number of people 3,423 8,459 27,921 18,636 15,555 
Number of VF records 16,162 65,355 285,552 113,847 121,523 
 
3.2.1 Inclusion and exclusion criteria 
SAP in these clinics, and most others in England, is routinely performed on a Humphrey Visual Field 
Analyzer (HFA, Carl Zeiss Meditec, Dublin, CA, USA). Only VFs recorded on the HFA using a 
Goldmann size III stimulus with a 24-2 test pattern acquired with the Swedish Interactive Testing 
Algorithm (SITA Standard or SITA Fast) were included, reducing the aggregated database to 576,615 
VFs from 71,361 people. SITA fast is commonly used in clinics in England. (Although SITA Standard 
is a more precise testing algorithm than SITA Fast at lower VF sensitivities, it is unlikely to make a 
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sizeable difference to improving the time to detect VF progression.[80]) In this specific study 
population, 83% of the recorded VFs were SITA Fast and the rest were SITA Standard. 
For the purpose of this report, the study population was defined as people in glaucoma clinics with 
measurable and sustained VF loss in at least one eye. This definition aims to exclude people suspected 
of having possible glaucoma (glaucoma suspects) and people with normal VFs and raised eye pressure 
(ocular hypertension [OHT]). Therefore, patients were only included if they had a VF with a HFA mean 
deviation (MD) flagged as outside the 95% normative limits in the HFA VF analysis software in at least 
one eye. (MD is a standard measure of the overall severity of VF loss, relative to healthy peers, with 
more negative values indicating greater VF loss). Moreover, this proxy criterion for measurable VF loss 
had to be satisfied for both of the first two VFs recorded in the clinic; this was done in order to improve 
the precision of the estimate of an individual likely to have real VF loss at their presentation to 
secondary care. The number of patients satisfying these criteria expressed as a percentage of the total 
number of people with a VF record was calculated. This can be thought of as a simple count of people 
in clinics with actual VF loss at presentation to secondary care (diagnosis) as opposed to, for example, 
being a glaucoma suspect, a false positive referral or having OHT.  
3.2.2 Metrics for assessing service delivery 
Six different metrics were calculated to characterise and estimate aspects of patient monitoring and 
outcomes in the clinics.  
Age at presentation was estimated by the age of the patient (years) at the time of their first VF record. 
Reliability of VFs was estimated by using the HFA false positive (FP) measure. It is accepted that HFA 
FP is a useful measure of a reliable examination.[31] The HFA-II flags VFs as unreliable if there are 
more than 33% FP errors. As these VFs were recorded using the HFA-II the FP cut-off used was 33%, 
although there are other potential values that could have been used. The more recent HFA-III, for 
example, sets the FP unreliable rate at 15%. Percentage of all VFs considered as unreliable due to FP 
errors was therefore determined for each centre.  
Stage of VF loss at presentation was estimated by MD in the worse eye (the one with the more negative 
MD) at the second VF examination. The second VF was used to ameliorate the bias of the perimetry 
learning effect.[97,98] The worse eye was chosen as a surrogate of the most ‘detectable’ level of VF 
loss at the stage of case finding in primary care. Patients with MD worse than -12 dB in this eye were 
defined as having advanced VF loss. Patients with MD better than -6 dB in this most affected eye were 
defined as having early VF loss, with all other patients classified as having moderate VF loss. These 
VF criteria have been used in health economic investigations of service delivery of glaucoma.[116,117] 
The proportion of patients within each of these three categories (early, moderate, advanced) can be 
summarised in a traffic-light waffle plot (green, yellow, red) for each centre. 
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Next, a subset of the study patients with sufficient series of VF examinations were defined as those with 
at least five VFs recorded over a period of four or more years. This subset of data were used for three 
more metrics summarising patient follow-up activity at each clinic. 
Speed (rate) of VF loss in clinics was determined by using simple linear regression of MD against time 
of follow-up (dB/year) and was only calculated in patients with series of data. The first VF examination 
in each series was removed to account for perimetric learning effects. These rates were then graphed 
for each centre by fitting a smoothing line to the peaks of a histogram (kernel density estimation vis the 
geom_density() function in ggplot2). 
Risk of VF loss blindness in clinics was estimated by a Loss of Sight Years (LSY) metric as described 
elsewhere.[115] In short, LSY estimates the number of years that a patient will have bilateral VF loss 
worse than MD of -22 dB (binocular VF impairment) in their predicted remaining lifetime.[87] The 
metric considers rate of VF loss in both eyes and the patient’s residual life expectancy based on age and 
sex as reported in UK Office of National Statistics.[118] Residual life expectancy takes into account 
that a person aged, for example, 80 years is more likely to live to age 81 years than someone aged 70 
years and is a useful measure of relative life expectancy. For patients with two eligible eyes with series 
of VF data it was determined whether LSY would be predicted to be longer than three years. The 
percentage of patients in each centre with this attribute was then calculated.  
Frequency of VF examination in clinics was simply estimated as the average interval (months) between 
recorded VF examinations during the follow-up period in those patients with series of VF data. 
Summary measures and distributions of these metrics were evaluated and compared for the five 
glaucoma clinics. Medians and interquartile ranges (IQRs) were used along with conservative non-
parametric tests to make simple, illustrative comparisons between clinics. All analyses were done using 
R (R Development Core Team, R: A Language and Environment for Statistical Computing, R 




Table 3.2: This table shows the summary measures of a number of metrics across the five centres (and 
a total column). The six main metrics highlighted in the methods section are given in bold font. Median 
(and interquartile range [IQR]) values or percentages are given in bold font. Median (and interquartile 
range [IQR]) values or percentages are reported as summary measures.  
 
 
 Centre 1 Centre  Centre 3 Centre 4 Centre 5 TOTAL 
Number of Patients with 
VF loss  
1,373 2,404 11,589 5,713 4,681 25,760 
Number of VFs 7,813 19,654 121,939 36,011 35,737 223,379 
Sex (% men) 45.6 45.2 47.1 47.7 44.8 46.5 
Median (IQR) 














% of unreliable VFs 3.0 4.4 5.1 4.3 4.1 4.6 














% patients with 
advanced VF loss at 
presentation 
29.6 25.0 24.2 23.0 22.8 24.0 
Number of Patients* 
with VF series >4 years 
843 1,786 9,208 3,917 3,480 19,264 
Median (IQR) MD loss 













% Patients LSY > 3 
years 
12.5 12.9 11.8 10.1 10.0 11.2 
Median (IQR) interval 















Application of the inclusion and exclusion criteria resulted in 223,379 VFs from 25,760 patients. 
Therefore 65.2% (n = 48,234) of people were excluded because they only had one VF examination or 
normal VFs in both eyes in their first or second VF examination. These people were excluded from 
further analysis. Series of VFs (more than 4 years of follow up) were available for 19,264 patients. 
Summary measures of the metrics for assessing glaucoma service delivery for the five centres (and the 
aggregate data) are given in Table 3.2.  
There was a statistically significant difference in the median age at presentation between the centres 
(p<0.001; Kruskal-Wallis test). Centre 1 had slightly older patients with little difference between the 
other centres. There was also a statistically significant difference between centres for percent of 
unreliable VFs (p<0.001; Chi Square test). Centre 1 (despite having older test takers) returned the lowest 
proportion of unreliable VFs. Differences between centres were generally small. Yet, for example, the 
rate of unreliable VFs recorded at Centre 3 was 1.7 times higher than that of Centre 1 (95% confidence 
interval for the relative risk of 1.4 to 1.9). It is noteworthy that around 1 in 20 VF examinations were 
unreliable according to this proxy measure across all centres. 
Stage of VF loss at presentation is also summarised as a series waffle (traffic light) plots for each centre 
in Figure 3.1. Centre 1 had notably more patients presenting with advanced VF loss when compared to 
the other centres. (Note this value summarises percent with advanced loss for those who present with 
some sort of VF loss. The value would be lower if the denominator was all people in the clinics.[81]) 
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Figure 3.1: A traffic-light (waffle) plot showing the classification of VF loss of newly presenting 
patients in each of the five centres. Each square represents 1% of the patients being classified as early 
(green), moderate (yellow) or advanced (red) VF loss on presentation. 
 
Speed (rate) of VF loss in the five clinics are summarised as distributions in Figure 3.2. The distributions 
were generally similar with the exception of centre 1 (and to a lesser extent centre 2); these distributions 
exhibited much heavier tails which means there were more eyes experiencing faster speed of loss VF 
loss at these centres compared to the others.  
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Figure 3.2: A plot showing the distribution of the speed of mean deviation (MD) loss (dB/year) in each 
of the five centres. Each line represents one of the centres. The distribution curves are obtained by using 
kernel density estimation to fit a smoothed curve to a histogram. Centre 1 (red) has a heavier tail 
compared with the other centres, indicating a higher proportion of patients with higher speeds of loss. 
Centre 1 also has a lower kurtosis (tail-to-peak ratio) and more negative skewness than the others. The 
coloured symbols on the x-axis indicate the median value for each centre (see Table 3.2). 
 
Risk of VF loss blindness as estimated by percentage of patients predicted to have LSY > 3 years was 
slightly greater in centre 2 (12.9%) when compared to the other centres and this was statistically 
significant (p < 0.001; Kruskal-Wallis test).  
Frequency of VF examination at the five clinics is summarised by distributions of the time interval in 
months between VF tests in Figure 3.3. Centre 4 had a noteworthy longer median time interval between 
VF tests (15.4 months) compared to the other centres and this was statistically significant (p <0.001; 




Figure 3.3: A plot showing the distributions of the time interval between patient visits (in months) in 
each of the five centres. Each line represents one of the centres. Centre 4 is more positively skewed, 
indicating a higher proportion of patients with longer intervals between visits. The coloured symbols 
indicate the median time interval between visits for each centre (see Table 3.2). 
 
One way of visualising speed of VF loss in clinics is to use a Hedgehog plot. [115] One of these is 
shown for Centre 1 in Figure 3.4. 
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Figure 3.4: A hedgehog plot showing the mean deviation loss over time of each eye in centre 1. Eyes 
highlighted in red indicate a speed of loss worse than −1.5 dB/year. The region marked in blue is a 
threshold for a severely impaired VF. More detail on these plots can be found in Bryan et al.[115]  
 
3.4 Discussion 
This work confirms that routinely collected VF data from glaucoma clinics can be downloaded, 
aggregated and anonymised from an EMR and be made available for analysis. This has previously been 
done for research purposes yet, here int this study it is illustrated how it could be done to potentially 
monitor and compare health service delivery at different glaucoma clinics.[80,81,84,87,120] For this 
exercise, assessments were done on anonymised centres with a key point of this work showing that this 
approach is feasible for future implementation. The logistics of the VF data extraction, which in this 
instance was carried out as part of the NOD work commissioned by HQIP, was not assessed. The 
amount of work carried out by NOD must not be understated, however. Even though only five centres 
are included in this study (and the other studies using this dataset) the actual NOD database contains 
records from 28 different hospitals and clinics. It takes an incredible amount of work to download, 
homogenise, clean, and collate the data from one database with linked patient data on surgeries, 
medications, demographics and so on. To do so with multiple centres is an impressive task and it is 
clear that a lot of care and diligence would have been needed to reduce the number of errors (missing 
data, incorrect data), a common trend in Big Data. Outside of the studies contained in this thesis, the 
group behind NOD have published a series of their own studies on the topic of cataract surgery as well 
as annual reports .[85,121–123] These highlight findings such as the (lack of) evidence of equity in 
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gaining access to cataract eye surgery as well as results surrounding the outcomes and complications of 
cataract surgery.  
This study has shown that assessment of VF records in glaucoma clinics could provide a first step 
towards quality improvement of services; this is a novel idea. For example, it has now been 
demonstrated how VF metrics of late presentation of glaucoma, or speed of loss of VF in people in 
glaucoma clinics during follow-up could be easily summarised for a clinical centre. It has also shown 
how it might be possible to compare the reliability and use of VF measurement between centres – for 
instance, it is feasible to identify centres that are doing more or fewer VF exams compared to others. 
The latter is important because it has been shown previously, via health economic modelling of 
retrospective data, that optimising use of VF resources could improve clinical management of patients 
and save money at the same time.[110] Since VF data can be held in EMRs this makes them amenable 
to automated and live analysis. This feasibility study indicates that this approach could be used to 
monitor what happens to people in different glaucoma clinics in real time. Assessment of quality 
improvement of glaucoma services with an implementation of this idea could be the subject of future 
work. 
The results from this report illustrate the feasibility of calculating metrics for assessing service delivery 
between centres using VF records alone. Nevertheless, some discussion about the differences in these 
metrics between the five anonymous centres is worthwhile. For example, centre 1 had more patients 
presenting with advanced VF loss and had more patients losing VF at a faster speed than other centres. 
These variables are highly associated in people with glaucoma and are, in turn, positively associated 
with older age.[1,84,110] It is noteworthy that patients in centre 1 were generally older than those in 
the other centres and this might, at least in part, explain these observations. Still, the chosen metric for 
risk of VF loss blindness as estimated by percentage of patients predicted to have LSY > 3 years was 
12.5% in centre 1. This observation underlines the importance of preventing late detection of VF loss 
for prevention of avoidable blindness.[87] The spread of time between visits also fluctuated quite 
significantly between centres. Centre 4 had the longest median time between visits and also had the 
widest range of IQR, indicating that follow-up times are highly variable between patients. This may be 
seen as a bad thing but when considering their performance metrics (VF rate of progression, presenting 
MD, reliability etc.) they are performing average or slightly above average compared to the other 
clinics. Why is that? It’s possible that the clinic has its own local guidelines in determining how long 
to wait before seeing a patient again. In Chapters 4 and 5, it will be shown that patients tend to have 
similar follow-up times irrespective of if they are a glaucoma suspect, OHT, POAG or POAG and 
uveitis. This “one size fit all” approach is not optimal and ideally the frequency with which patients are 
seen should be based on the suspected need (more severe = seen sooner, less severe = seen less soon). 
If Centre 4 was implementing something such as this, it could lead to the sort of results reported. An 
additional discussion on the variability between centres and possible effect on findings is in Chapter 7. 
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This report reveals some other interesting subsidiary findings. The population for this report is people 
with measurable VF loss in glaucoma clinics (at least two VFs with actual VF loss as measured by MD). 
These inclusion criteria reduced the sample by 65.2%. In other words, around two-thirds of people with 
HFA 24-2 VF records in these data sets had single ‘one-off’ VFs or had normal VFs at presentation to 
the clinics. This figure illustrates the huge volume of likely false positive glaucoma referrals, glaucoma 
suspects and ocular hypertensive that glaucoma clinics deal with on a daily basis. Moreover, around 1 
in 20 VFs are recorded with reliability indices outside normal limits. In addition, the median interval 
between VF tests in people being followed over time was 11.2 months and as high as 15.4 months in 
one centre. This supports previous findings that annual VF testing is the norm for most patients in 
glaucoma clinics in England.[77] Heath economic modelling has highlighted the benefits of stratifying 
patients to more or less VF monitoring based on age and stage of disease at diagnosis; a prospective 
study is needed to prove these findings.[110] 
Using EMRs for research or audit is not a new idea, having been implemented in many fields of 
medicine to study diseases such as diabetes, heart failure, cancer and asthma.[53] In eye clinics EMRs 
have been used for audit of cataract surgical outcomes but importantly also have potential for making  
health care delivery more efficient by facilitating more streamlined clinical work flow, better patient 
management and improved data tracking.[61,62,85,124–127] However, ideas and implementation are 
different entities and meaningful use of EMRs in ophthalmology is still a work in progress.[54,55,128] 
Presently, certainly in clinics in England, there are challenges about how clinical data are recorded, 
archived and stored. Moreover, issues such as non-collated datasets, duplicate IDs and differing 
databases add to the challenge of moving towards comprehensive use of EMRs. 
This approach to the concept of assessing service delivery in glaucoma clinics has several strengths. In 
theory, VF records should be easily stored on EMRs making them amenable to easy extraction, analysis 
and audit. Whether this happens in practice is dependent on the motivation of implementing electronic 
archiving of VF examinations and use of EMRs in hospital eye services. Another rational for using VF 
metrics is their relevance to measuring vision. IOP is the only modifiable risk factor for glaucoma 
progression and is crucial to patient management but VF metrics will best estimate the status of people’s 
vision loss in the clinic. The approach in this audit does not consider everyone in glaucoma clinics but 
centres on those with a proxy measure of sustained VF loss. These patients are at higher risk of further 
significant vision loss in their lifetime when compared, for example, to people with ocular 
hypertension.[55,87,128,129]   
There are limitations to the ideas reported in this study. The main problem is reliance on the VF data 
alone. A more complete assessment of what is happening in a glaucoma clinic would be achieved by 
considering exact diagnosis, treatment regimens, intraocular pressure, optic nerve head characteristics, 
individual patient history, or other risk factors. For example, much can be learnt about what is happening 
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in glaucoma clinics by reviewing repositories of data on prescribed medications. [130] However, EMRs 
need an established and standardised minimum data set for glaucoma care and this is the subject of 
future work. This idea will also be limited to how well VF records can be archived at a centre. The five 
sites chosen for this study were all EMR enabled and known to run large glaucoma services with 
aggregated electronic VF databases. Alternative options could include separate data extractions from 
individual machines with subsequent aggregation into a single database, but this would be time 
consuming and carry significant cost, in particular if these services were delivered in different settings 
such as outreach clinics. A possible limitation of this approach in general is that not all clinics/centres 
are the same. When comparing large numbers of centres, it’s important to note whether they are primary, 
secondary or tertiary care centres and compare appropriately. 
There are also limitations to some of the proposed metrics for assessing service delivery. First, while 
MD is a useful summary measure of how much sensitivity loss there is in a VF and particularly 
convenient to monitor changes over time, it is not a perfect measure for glaucomatous VF loss. MD can 
be affected by non-glaucomatous changes such as a general reduction in VF sensitivity caused by, for 
example, cataract. Second, as noted previously, only the FP reliability index was used as a measure of 
patient test taking performance.[31] Of course this measure, or any other similar measure, would not 
capture patients failing to complete an exam or those excluded because of a previous failure to reliably 
conduct a VF examination. Third, the measure of “risk of blindness” (LSY) makes a number of 
assumptions around residual life expectancy and progression of VF loss being constantly linear. Fourth, 
when comparing metrics it will also be important to consider some centres simply differ in terms of 
population factors (e.g. racial and socio-economic profile) and audits using the methods proposed in 
any report would have to take this into account. Finally, if this approach were to be extended into a 
national audit, as I believe should be an eventual goal of the NHS, several challenges would first need 
to be overcome. The integration of every centre into a national database would take a considerable 
amount of time and money. It may also involve the learning or re-learning of the new systems put in 
place by both clinicians and technical staff. Maintaining adequate upkeep of this sort of database, 
implementing offline and offsite backups as well as ensuring high levels of security/data protections 
would itself take additional time and resources. Issues around data protection and data sharing within 
ophthalmology have been highlighted recently, whereby anonymised patient data is assumed to be 
available for research. Patients are unable to opt out of certain research projects (such as ones being 
carried out by large multinational corporations) but opt into research being carried out at a more local 
level. Going forward, clarification around this data sharing and perhaps a more stratified opt-out system 
will be needed. If these issues are overcome however, such a sophisticated network would have benefits 
for clinicians and researchers, allowing for real-time audit of how clinics are performing. The outcomes 
of changes in policy or guidelines would be easy to measure allowing for rapid feedback. 
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The amount of data and the complexity of data being collected within healthcare is constantly 
increasing. Newer imaging paradigms, while incredibly useful also take up large amounts of storage 
space. All of these images and records need to be stored somewhere. They need to be accessible from 
anywhere on a network. The end result of this is an exponential increase in the amount of data 
throughput hospital servers need to handle. Smart techniques to handle data can only go so far and many 
systems currently are not ready to deal with the increases in requirements. A multi-pronged approach 
will be needed in the future. 
In conclusion, this study illustrates the feasibility of assessing some aspects of quality of care in 
glaucoma clinics through analysis of VF databases from EMR enabled centres. This approach, which 
is outcome focussed, is a potentially useful method for assessing blindness prevention from glaucoma 
in secondary care centres. VF testing technology is standardised in the UK NHS and although in many 
centres the electronic VF tests will be distributed across several VF testing machines it is feasible to 
aggregate these fields into a central database located in each centre for central analysis. Ideally, such a 
central field database would reside within a specialty specific EMR implementation serving both 
clinical and quality assurance needs. Secondary benefits from such an approach would include the 
ability to more easily detect patients whose VF loss is progressing rapidly in order to intensify their 
treatment as well as detection of those patients whose VFs are stable who may require less intensive 
monitoring once VF stability has been documented. By shifting focus towards those in most need, health 
services resources can be more effectively utilised. In the current NHS digital environment, a variety of 
challenges would need to be overcome in order to extend this audit approach into a national audit of 






4 Using electronic medical records to investigate the conversion from 
ocular hypertension to primary open angle glaucoma 
The work presented in this chapter has formed a paper submitted to the British Journal of 
Ophthalmology; see list of supporting publications. The authors on this paper are SRK, Susan Bryan 
(SB), Anthony Khawaja (AK), John Sparrow (JS), Augusto Azuara-Blanco (AAB) and David Crabb 
(DC). The entire analysis contained in the study (including coding and production of figures) was 
carried out by SRK as well as the drafting of the manuscript. The manuscript was then reviewed and 
edited by SB, AK and DC. AAB and JS acted as advisors during the manuscript review process but 
were not involved directly in the study. 
4.1 Introduction 
Referral guidelines for ocular hypertension (OHT) or other glaucoma related conditions in England 
currently require evidence of optic nerve head damage, a VF defect consistent with glaucoma or an IOP 
of 24 mmHg or more measured using Goldmann-type applanation tonometry.[4] Before referring, the 
clinician may repeat the IOP measurement or VF assessment to confirm glaucomatous-type signs before 
referral. The EPIC-Norfolk study recently reported a prevalence of 10% for OHT (IOP >21 mm Hg, 
based on previous guidelines) in the English county of Norfolk.[15] This is based on a mostly Caucasian 
population and there is evidence that OHT is more prevalent among other ethnic groups, specifically 
blacks. Specifically the Barbados Eye Study found the incidence of IOP above 22 mmHg to be five 
times higher in blacks than in whites.[131] Current guidance states that IOP-lowering eye drops may 
be offered to patients with high IOP if they are at risk of visual impairment in their lifetime.[4] The 
reported rate of conversion from OHT to POAG is variable in the literature.[5,132–134] Robust data on 
the likelihood of developing glaucoma for those with OHT are required to inform monitoring guidelines 
in terms of effectiveness, cost-effectiveness and acceptability to all patients, eye care providers and 
commissioners of NHS services.  
Since there is a risk of developing glaucoma, patients with OHT are monitored using a similar testing 
regime that POAG patients receive. Standard UK practice as such is to monitor in secondary care. This 
places a strain both on eye care services and the people affected as monitoring in specialist eye clinics 
can be inconvenient, may lead to ‘over treatment’ and is expensive for the NHS.[15] As up to half of 
POAG is characterised as normal tension glaucoma (NTG) in Europeans, high IOP is neither a 
necessary nor a sufficient condition of glaucoma.[15,135] Therefore, it is likely that a proportion of 
patients with OHT are receiving unnecessarily close follow-up or treatment. With an aging population 
and an increase in optometric screening, the number of patients being seen in clinics with glaucoma 
related conditions is expected to rise, placing further strain on these services.[20] 
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Healthcare clinics in the UK are transitioning to some form of EMR system to store patient data 
digitally, although progress is slow.[69,136] Glaucoma clinics in particular have the ability to store data 
relevant to OHT patients such as IOP readings, VF test results and which medications (if any) they are 
taking. The aims of this study were to use EMR data from five glaucoma clinics in England to 
retrospectively analyse OHT patients. The primary aim was to estimate the proportion of OHT cases 
that progressed to VF loss within 5 years and to examine factors associated with this progression. The 
secondary goal was to consider the burden that OHT patients have on glaucoma clinics, relative to other 
conditions such as POAG and glaucoma suspects. 
4.2 Materials and methods: 
Information on the source of the data can be found in preceding Dataset 2 primer. The study adhered to 
the Declaration of Helsinki and all analyses of the data were approved by a research ethics committee 
of City, University of London. All patient data were anonymised and securely held on the university 
database. 
4.2.1 Inclusion criteria 
In this analysis, only one eye per patient was included. To be included, a patient needed an eye with a 
clinical diagnosis label of OHT with no prior glaucoma-related diagnoses (similarly for the fellow eye) 
and with no disallowed comorbidities. Eyes with a visual acuity (VA) worse than 6/19 were excluded. 
Eyes were also excluded if they were labelled with a diagnosis label of cataract, corneal condition or 
eye casualty. Eyes with age-related macular degeneration (AMD), for example, were included if they 
had a VA better than 6/19. If both eyes were eligible, the eye with the highest baseline IOP was chosen. 
As the risk of VF loss is being considered at a patient level, VF loss to either eye would qualify. As 
such the eye with the higher IOP was picked for this analysis as it is at a higher risk of VF loss. If both 
eyes had the same baseline IOP, one eye was chosen at random. For the purpose of this study, only VFs 
tested by using the Humphrey Field Analyzer (Carl Zeiss Meditec, Dublin, CA) with the 24-2, white-
on-white test strategy acquired with the Swedish Interactive Testing Algorithm (SITA Standard or SITA 
Fast) were included in the analysis. A minimum of 3 reliable VF tests were needed, one to measure the 
baseline readings and two consecutive reliable examinations showing potential repeated VF loss. 
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Figure 4.1: Flowchart of where patients were included/excluded. The flowchart also shows the predicted 




To classify patients into different levels of VF damage the glaucoma staging system 2 (GSS2) described 
by Brusini and colleagues was used.[137] This system classifies VF damage into one of seven 
progressively worsening categories based on MD and PSD values. There are situations where a person 
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may have a poor MD value (highly negative) but a normal or mild PSD value. This can occur due to 
diffuse VF suppression from eye conditions such as cataracts. If using MD alone, these patients would 
have resembled glaucoma patients despite not having typical glaucomatous VF damage. By 
incorporating PSD into the staging system, the patient population can more accurately be filtered for 
those with no/early glaucomatous VF damage. The GSS2 was adapted for use with the 24-2 SITA 
testing strategies (the original GSS2 uses values from full threshold strategies). The desired study 
population was “true” OHT patients (i.e. with little-to-no VF damage). As such only patients classified 
as one of the two early stages (Stage 0 or Borderline) were included. If an eye is diagnosed as OHT but 
has a high GSS2 stage (usually indicating a high level of VF loss), this could mean that either the 
diagnosis was not updated, or the patent was unable to reliably perform VF testing. Baseline VF was 
defined as the VF closest to the time of diagnosis labelling, with a maximum of one year between the 
diagnosis and VF test. Baseline stages as measured by the GSS2 for all included eyes can be seen in 
Figure 4.2A. The measurement of the last recorded follow-up visit is also shown  in Figure 4.2B. There 
was no upper limit set for this plot so some patients visible have over 5 years of follow-up. 
Figure 4.2: A glaucoma staging system 2 scatterplot showing the eyes included for analysis. Only eyes 
with a baseline measurement in the early stages (stage 0 [green] or borderline [orange] stage, demarked 
by a red curve) were included (Figure 4.2A). A second scatterplot illustrating the GSS2 stage of the last 






4.2.2  Statistical Analysis 
Follow up VF data was considered for up to 5 years following diagnosis of OHT. Any visits after this 
5-year window were excluded. Two consecutive reliable VF exams with a GSS2 classification of stage 
1 or worse was used to define VF loss. The VF with the earlier date was considered as the date of 
progression. Patients with less than 5 years follow-up were included in the analysis but censored. 
Cox Proportional-Hazards regression analysis was used to examine the factors associated with incident 
VF loss and several models were fitted. Baseline age (years), sex (man vs woman), baseline IOP (mm 
Hg) and treatment group (treated vs untreated) were examined both univariably and then together. The 
treated group was defined as eyes that had a record of IOP-lowering medication or surgery, while being 
labelled as an OHT patient. The untreated group was defined as eyes that were recorded in the 
medication database but did not have any glaucoma medication listed and had no recorded glaucoma 
surgeries. Three models were selected for reporting. A simple (no predictor variables) all-cause survival 
curve and a survival curve with treatment group as a predictor variable are shown in Figure 4.2. The 
results for the multivariable cox regression are shown in Table 4.2. 
The relative burden of glaucoma suspect patients, OHT patients and POAG patients on the glaucoma 
clinics was estimated. This was defined as the relative proportion of unique clinic visits (for IOP or VF 
measurements) for each of the three clinical diagnosis labels. A visit for one of the labels, say OHT, 
was defined as a visit date that occurred in the range of dates while the eye of interest was labelled as 
OHT. If the diagnosis label was updated at a later date, for example from OHT to POAG, then 
subsequent visits would be counted as POAG visits. A visit where both eyes had the same label, would 
be counted as one visit for that label. A visit where both eyes had different labels, would be counted as 
a visit for the more “serious” label (where POAG is considered more serious than glaucoma suspect, 
which is considered more serious than OHT). The average number of months between VF tests for 
patients with at least 4 visits was calculated. All analyses were performed within the open-source 
statistical programming environment R.[119] 
4.3 Results: 
4.3.1  Baseline Characteristics 
From the initial cohort of 9524 patients with a clinician diagnosis label of OHT, 3163 were included in 
the final analysis (see Figure 4.1 for inclusion flow chart). Of these, 1716/3163 (54%) were women, 
2202 (70%) were on IOP lowering treatment during their OHT diagnosis and 1531 (48%) of the eyes 
were right eyes. Other descriptive statistics can be found in Table 4.1.  
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Table 4.1: Statistics of included patients 
Included 
(n) 
Median (IQR) age at 
diagnosis (years) 
Median (IQR) Baseline 
IOP (mmHg) 
Median (IQR) follow-
up IOP (mmHg) 
Median (IQR) Baseline 
MD (dB) 
3,163 60 (51, 66) 24 (20, 27) 20.75 (18.33, 23.00) -0.45 (-1.32, 0.34) 
 
4.3.2 Cox PH analysis  
The survival analysis curves can be seen in Figure 4.3. All-cause predicted progression after 5 years 
was 17.5%. (Figure 4.3A). When stratified by treated and untreated groups, the predicted progression 
after 5 years was 14.0% and 26.9% respectively (Figure 4.3B). Results of the Cox multivariable 
regression can be found in Table 4.2. The hazard ratio of VF progression while on IOP-lowering 
treatment versus no treatment was 0.45 (95% CI: 0.35 – 0.57). The hazard ratio of VF progression per 
year increase of baseline age was 1.03 (95% CI: 1.02 – 1.04). The hazard ratios of both baseline IOP 




Figure 4.3: Cox PH survival curve of 5-year progression predictions for (A) all patients (green) and (B) 
the treated (blue) and untreated (red) groups with the 95% confidence intervals. The risk table shows 
the number of patients still included in the analysis for a group at each 1-year interval. The cumulative 







Table 4.2: Results of Cox PH survival analyses 
Variable Name Hazard Ratio P value 




Sex (F) 1.01 0.95 
Treatment (Yes) 0.45 < 0.001 
 
4.3.3  Burden on clinics 
Of the total number of unique visits (recording either a VF or IOP measurement) for the three clinical 
labels included for analysis, 21% were recorded for glaucoma suspect patients, 22% for OHT patients 
and 57% for POAG patients. If only VF measurements are considered, the distribution is 23%, 23% 
and 54% for glaucoma suspects, OHT and POAG patients respectively. For IOP measurements the 
distribution is 20%, 23% and 57%. 
The survival analysis predicts that around one in six (17.5%) OHT patients will have detectable VF loss 
within five years. Of these, 70% are receiving IOP-lowering treatment. OHT patients receiving IOP-
lowering treatment have a lower rate of predicted progression of around one in eight (14%). This 
indicates that there are many OHT patients in the clinic, especially those who are being treated, that are 
unlikely to lose much VF function within a five-year window. If only 3163 patients that were included 
in the survival analysis are considered, 11727 of 15464 (76%) of the visits within the five-year study 
window were recorded while the eye was receiving IOP-lowering treatment. This corresponds to 76% 
and 74% of the IOP and VF measurements respectively. For patients with at least 4 VF visits, the 
average time between VF tests was 10.9, 9.7 and 9.6 months for glaucoma suspects, OHT patients and 
POAG patients respectively, showing that OHT patients are seen as frequently as POAG patients. 
 
4.4 Discussion:  
The aim of this study was to estimate the likelihood that a newly diagnosed OHT patient would suffer 
from VF loss within five years. The figures in Table 4.1 show that a relatively high number of eyes 
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(3163) were included in the analysis, despite a reasonably strict inclusion criterion. The results from the 
survival analysis predicts that 17.5% of patients in the data would progress to a worse VF stage (per the 
GSS2) within the study period of five years (Figure 4.2A). Although not all included patients had at 
least 5 years of follow up time, the survival analysis handles these data with right-censoring. When 
comparing treated eyes and untreated eyes, it was found that 70% (2202/3163) of the OHT eyes had 
some form of IOP-lowering medication or surgery during their OHT diagnosis. The survival curve 
analyses show that the treated eyes were predicted to progress to VF loss significantly less than the 
untreated eyes with 14% and 26.9% respectively (Hazard ratio: 0.45, 95% CI: 0.35 – 0.57) (Figure 
4.2B). A caveat of using this retrospective observational data is that it cannot be said for sure that the 
treatment and lower rate of progress had a cause-effect relationship. Instead, it is more sensible to report 
that there was a significant association. Baseline age was also a statistically significant predictor, with 
a one-year increase indicating a hazard ratio of 1.03 (95% CI: 1.02 – 1.04). 
According to these data, more than one in five (22%) unique clinic visits were for OHT patients, relative 
to POAG and glaucoma Suspects. If only 17.5% of patients are predicted to have detectable VF loss 
within five years, is it necessary that they be seen in secondary care clinics this frequently, considering 
that the risk of significant vision loss is very low (only 1.75% of this study population reaching severe 
VF loss)? There are several alternative options available that would reduce the burden on hospitals and 
glaucoma clinics, such as monitoring patients in primary care practices or in virtual clinics. So-called 
‘shared care’ schemes could be a possible approach for low risk OHT patients.[20,138,139] Notably, 
OHT patients had VF testing as frequently as both POAG and glaucoma suspect patients further 
emphasising that OHT patients are using a disproportionate amount of resources, relative to the 
immediate risk of VF loss. One suggestion to reduce the burden of OHT patients could be to increase 
the follow-up period between appointments.[20] Morley and Murdoch estimated that increasing time 
between follow-up visits by a factor of 1.5 could reduce the relative clinic workload by 30%. If the 
follow-up time was increased by a similar factor for stable, low-risk OHT patients, it could free up 
resources for high-risk or new patients. 
According to the National Institute for Health and Clinical Excellence (NICE) glaucoma guidelines, 1.3 
million people over aged 40 in the UK have high eye pressure (above 24 mmHg) and those who have 
this condition are monitored in hospital eye services.[4] The rate of progression from OHT to POAG is 
variable in the literature. In a large multicentre clinical trial, the Ocular Hypertension Treatment Study 
(OHTS), the cumulative probability of developing POAG at 5 years was 9.5% in the untreated group 
and 4.4% in the treated group.[16] In another study, the European Glaucoma Prevention Study (EGPS), 
the progression rates were 13.7% and 16.4% for the treated and untreated groups respectively [133].  
The results in this chapter likely underestimates the number of OHT patients converting to POAG, since 
the dataset lacked any sort of structural data (including CCT) and could only consider VF outcomes. 
Also, only patients with no comorbidities and a baseline VF stage of 0 or borderline using the GSS2 
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were considered, which could further skew results. The results, however, still seem to be relatively high 
when compared with the above trials.  
When designing the study protocol, one option was to consider a change of diagnosis label as an 
outcome for progression. The centres varied significantly in their labelling conventions and often, labels 
were not being updated (to say, POAG) despite there being obvious, repeatable VF defects. Moreover, 
one centre had little-to-no diagnosis labelling, while another had a much higher rate of label changing. 
As such, it was decided to opt for the more objective approach of looking at VF loss alone. While still 
relying on these subjective labels to define the study population, the labels are only used once to 
establish a baseline, instead of twice to also mark progression. For added a baseline VF measurement 
indicating no VF damage, as classified by the GSS2 was also required. As the dataset did not include 
any biometric data (such as optic nerve measurements) this study does not examine OHT patients 
progressing to POAG in a clinical sense, but rather investigating the likelihood of developing VF loss 
in OHT patients. 
The diagnosis labels and dates of diagnosis used in this study to select OHT patients are to be interpreted 
as surrogates of disease presentation. For this analysis, the first recorded date in the EMR was used as 
a surrogate of when the disease began. However, it is sometimes the case that patients come into a clinic 
previously diagnosed with OHT and already are being treated for some time before being entered into 
the EMR. 
Retrospective analyses such as this are only possible if the data is recorded electronically in a structured 
way. If this data were recorded via an open text box (as opposed to mandatory text fields) or on pen and 
paper, this type of study would not be feasible. Today, most medical record systems are being digitised 
which makes the possibility of large, multi-centre studies using Big Data much more feasible.[69] As 
these data are already being recorded routinely, there is an opportunity of relatively cheap and accessible 
healthcare research to be gained from exploring them. Moreover, as this data comes straight from 
clinics, it can tell us more about what goes on in real-world scenarios, which could inform how we 
organise our healthcare systems. 
The results from this study highlights an important issue recently experienced in glaucoma clinics 
around the UK. Since primary care facilities for the most part only have the facilities to measure IOP, 
large numbers of patients were being referred to secondary care clinics on IOP alone. The vast majority 
of these patients are at no risk of sight loss in the near future and yet they take up a large portion of time 
and resources. This can hopefully help to inform clinicians for OHT-specific guidelines with regards to 
the frequency of which these patients are being seen and the potentially unnecessary burden they have 
on secondary care facilities.  
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5 Using electronic medical records to investigate patients with uveitis 
and POAG 
The work presented in this chapter has formed a paper published in the American Journal of 
Ophthalmology (Liu et al. 2019); see list of supporting publications. The authors on this paper are SRK,  
Xiaoxuan Liu (XL, who was a joint-first author with SRK), Giovanni Montesano (GM), Susan Bryan 
(SB), Robert Barry (RB), Pearse Keane (PK), Alastair Denniston (AD) and David Crabb (DC). Most 
of the statistical analysis (as well as all the related code and figures) contained in the study were carried 
out by SRK. GM contributed to the development of the mixed-effects model. The drafting of the 
manuscript was carried out by SRK (methods and results) and XL (introduction and discussion) which 
was reviewed and edited by GM, SB, AD and DC. RB and PK acted as advisors during the manuscript 
review phase but were not involved directly in the study. This work was presented as a paper 
presentation at several conferences by XL (ARVO 2018, UKÉGS 2018 and EURETINA 2019). 
5.1 Introduction: 
Uveitis remains the fourth most common cause of blindness in the working-age population throughout 
the developed world, with visual impairment affecting between 2.8 and 10% of uveitic patients.[140–
143] Reduced visual function may result from direct damage to uveal tract structures, but more 
commonly occurs due to secondary tissue damage, with the most prevalent complications being 
cataract, macular oedema and glaucoma.[67] Of these, both cataract and macular oedema can be 
considered at least partially reversible, however visual impairment due to glaucoma is irreversible and 
thus early diagnosis and appropriate management of uveitic glaucoma is of paramount importance.   
Glaucoma in the presence of uveitis can develop via a number of mechanisms.[144] Increases in 
intraocular pressure (IOP) can occur due to mechanical obstruction of aqueous outflow, presenting with 
secondary angle closure due to pupillary block from posterior synechiae, or more chronically following 
development of peripheral anterior synechiae or angle rubeosis. Secondary open angle glaucoma may 
develop due to chronic inflammatory damage to the trabecular meshwork, or in response to 
corticosteroid therapy. In addition, specific uveitis entities are associated with elevation of IOP, such 
Posner-Schlossmann syndrome, Fuch’s heterochromic iridocyclitis and herpetic uveitis. Active 
inflammation, corticosteroid usage, increasing age, and number of years since diagnosis have each been 
demonstrated to be associated with raised IOP in uveitic patients.[145] 
The prevalence of raised IOP in uveitis remains poorly defined, since increases in IOP may be transient 
and may not progress to true glaucomatous optic neuropathy. The prevalence of treated glaucoma varies 
from 20-30% in most cohorts.[67,145–147] Accurate stratification of patients at risk of uveitic 
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glaucoma is necessary to identify those at high risk of irreversible vision loss. Intensive monitoring and 
active intervention are important to prevent irreversible visual impairment in these patients.[6]  
With the widespread adoption of EMRs, it is now possible to collect clinical data from large patient 
populations, identifying trends in disease progression and treatment response which have not been 
possible with traditional paper-based records. Such Big Data approaches have been successfully used 
to characterise the population and predict outcomes in other ophthalmic diseases.[29,64,65,84,87] This 
study aims to utilise large-scale EMR data for comparing the rate of VF loss in uveitis patients with 





Information regarding the dataset can be found in the preceding Dataset 2 primer. 
Figure 5.1: Flow chart showing the inclusion criteria leading to a study sample of 4,600 POAG eyes 
and 205 UG eyes for the VF analysis and 3,386 POAG eyes and 143 UG eyes for the IOP analysis. 
Number of “fast progressors” in the VF analysis are also shown. Centre 4 is highlighted in red as it was 
missing a large amount of diagnosis data. 
 
5.2.1 Inclusion criteria 
Eyes were sorted into two groups based on EMR diagnostic labelling: a POAG group and a group of 
patients with both a ‘uveitis’ and ‘glaucoma’ diagnosis. POAG was defined by having a diagnostic label 
of ‘POAG’ or ‘chronic open angle glaucoma (COAG)’ without any uveitis co-pathologies. Uveitis plus 
glaucoma was defined as having both a label of POAG or COAG plus a uveitis label. A variety of 
anatomical and disease-specific labels for uveitis were included. Initial extraction by diagnosis found 
1,179 eyes with uveitic glaucoma and 21 209 eyes with POAG (Figure 5.1). The inclusion criteria for 
each eye was a minimum of 4 VF tests over 4 years, with at least 4 of the included tests being performed 
within the initial 4 years (Figure 5.2). Often times the first visual field is excluded to mitigate potential 
learning effects. The first visit is included in this study as the power of the linear regressions was higher 
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with it included, despite the potential underestimation of VF sensitivity.  Only VFs from the Humphrey 
Field Analyser (HFA) using Goldmann size III (white-on-white) stimuli with the 24-2 test pattern 
acquired with either SITA Standard or SITA Fast testing algorithms were included. 
Figure 5.2: A schematic illustrating the VF series inclusion criteria and method for calculating rates of 
MD loss (dB/year) for two example eyes. Eyes were excluded if <4 VF examinations of <4 years of 
follow-up. Rates of VF loss were calculated from ordinary least squares linear regression of the baseline 
VF and the series of exams that fell within a 4-year window period after it (white window). In the top 
example, the 5th, 6th and 7th recorded VFs fall outside of the window and were not used in the 
calculation. In the bottom example, only the seventh exam was excluded. This ensures that all rates are 
estimated with equivalent precision, allowing for comparisons over time. 
  
A secondary analysis on the association between IOP behaviour and VF progression was also carried 
out. In addition to the above inclusion criteria, a minimum of 4 IOP measurements in the first 4 years 
were needed.  
5.2.2  Statistical analysis 
Analysis was carried out on one eye per patient; if a patient had two eligible eyes, one was chosen at 
random. The first VF examination of each series was defined as the baseline measurement. HFA 
pointwise sensitivity values and mean deviation (MD; an estimate of average VF sensitivity relative to 
healthy age matched controls) values were extracted for each VF for each eye. Pattern deviation (PD) 
pointwise values were calculated using the visualFields package in R.[148]  
68 
 
Ordinary least-squares (OLS) linear regression of MD over time was used to estimate rates of 
progression (dB/year). As with previous studies, a fast progressing VF series was defined as having a 
rate of progression slope of  ≥1.5 dB/year.[84,110] A crude relative risk (RR) was calculated as the 
ratio of the proportion of fast progressors in the uveitis and POAG groups, for each 10-year age group 
from 40 to 100 years, as estimated by the OLS regression slopes. An overall age-adjusted RR was 
calculated using the direct method.[149] 
Two secondary VF progression analyses were also performed. First, a linear mixed-effects model 
analysis, which can estimate the regression coefficient while including both fixed and random effects 
was fitted.[150] A brief explanation of mixed-effects models can be found in Chapter1 .MD was treated 
as a response variable, time (years since first visit), group (POAG or uveitis) and baseline age were 
treated as fixed effects and individuals as a random effect. 
Second, the permutation of pointwise linear regression (PoPLR) technique was used to analyse the 
pointwise sensitivities and PD values of each VF series.[151–153]A summary of this is also given in 
Chapter 1. The outcome of interest is simply the proportion of eyes showing statistically significant 
progression (at p = 0.05) in the uveitic and POAG groups. 
IOP data were analysed using longitudinal metrics: mean, range and mean absolute error (MAE). Mean 
IOP was defined as the mean of all recorded IOP values in the series. IOP range was defined as the 
highest value (peak) minus the lowest value (trough) in the IOP series. MAE, as a measure of IOP 
variability, was estimated by fitting an OLS linear regression to IOP values over time, then extracting 
errors (predicted values minus the observed IOP) at each visit. The mean of the absolute values of these 
errors was the MAE value. Univariate associations between rates of progression and IOP metrics were 
analysed. Statistical comparisons were made using the Mann-Whitney U test. 
Analysis was caried out using R (R Development Core Team, R Foundation for Statistical Computing, 
Vienna, Austria). 
5.3 Results: 
5.3.1 Baseline Characteristics 
From a starting population of 1,179 eyes, 205 (17%) eyes with uveitis plus glaucoma satisfied the 
inclusion criteria and were included in further analysis. From a starting population of 21,209 eyes, 4,600 
(22%) eyes with POAG were included in further analysis (Figure 5.2). Median (interquartile range 
[IQR]) age of the patients was 64 (53, 73) and 70 (62, 76) years in the uveitis and POAG groups 
respectively. Baseline MD model estimates in the uveitis and POAG groups were –5.55 (95% CI: -6.39, 
-4.47) dB and –4.47 (95% CI: -4.31, -4.63) dB respectively. Median (IQR) Intensity (frequency) of VF 
testing was the same, with an interval of 10 months between each VF test, for both groups. 
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5.3.2 Rate of Visual Field loss 
The uveitis and POAG groups had 23/205 (11%) and 331/4 600 (7%) eyes which progressed at ≥1.5 
dB/year respectively. The crude RR of a fast rate of progression for uveitis/POAG was 1.6 (95% 
confidence interval [CI] 1.1 – 2.3) and age-adjusted RR was 1.9 (95% CI: 1.8 - 2.0). This indicates that, 
for a similarly aged population, a patient in the uveitis group was 1.9 times more likely to be a fast 
progressor than patients in the POAG group. 
Further analysis using the mixed effects model showed that, the age-adjusted rate of progression was -
0.49 dB/year for the uveitis group and -0.37 dB/year for the POAG group. The estimated average age-
corrected difference in rate of progression between the groups at the mean age was -0.12 dB/year (p < 
0.01) 
VF progression analysis using PoPLR on PD values indicates that the uveitis group has a higher 
proportion of significantly progressing eyes (21.2%), compared to the POAG group (18.5%).  
5.3.3 Longitudinal intraocular pressure (IOP) analysis 
A total of 143 eyes with uveitis plus glaucoma and 3,386 eyes with POAG met the additional inclusion 
criteria for longitudinal IOP analysis. A summary of longitudinal IOP measurements can be found in 
Table 5.1. There was no statistically significant difference in mean IOP (within 1 mmHg) between the 
two groups, yet there was wider range and higher MAE in the uveitis group (p<0.001). A comparison 
between fast and non-fast progressors found the mean IOP difference to be within 1 mmHg for all 
groups. IOP range was wider in the fast progressors of both POAG and uveitis groups (both p<0.05), 
and widest in the fast progressing uveitis group (21 mmHg). Similarly, MAE was higher in fast 




Table 5.1: Longitudinal Intraocular Pressure Metrics: Comparison Between Primary Open-Angle 
Glaucoma and Uveitis Plus Glaucoma Groups 
IOP (mm Hg), 
Median (IQR) 




(N = 143) 
 




P = .445 




P < .001* 
Mean absolute 
error 




















P = .827 








P = .040* 
Mean absolute 
error 
2.1 (1.6, 2.8) 2.3 (1.7, 3.2) P < .001* 2.6 (1.8, 2.9) 3.5 (2.3, 6.1) P = .051 
 
5.4 Discussion: 
This is the first study to utilize real world EMR data to compare rates of VF loss in uveitis patients with 
glaucoma and those with POAG. It was demonstrated that uveitis patients with a diagnosis of glaucoma 
were likely to be younger and have a worse MD at baseline than those with a diagnosis of POAG. The 
uveitis group were more likely to lose VF at a rapid rate (≥1.5 dB/year loss in MD) compared with the 
POAG group, with an age-adjusted RR of 1.9 (95% CI: 1.8 - 2.0). Despite this, the data show that the 
average frequency of VF monitoring is the same for both diseases. The longitudinal IOP analysis 
suggests IOP range and variability had a stronger association with rapid VF loss than mean IOP. 
These findings suggest that patients with a combination of uveitis and glaucoma lose vision more 
rapidly than POAG, yet on average they are monitored with VFs at the same intensity. These estimates 
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of rate of VF loss in POAG (-0.37 dB/year) is higher than previously been reported in the literature, 
however these estimates differ in that were adjusted for age.[84,154] The observed proportion of fast 
progressors in the POAG cohort is also similar to previous studies: defined thresholds for ‘fast’ or 
‘rapid’ progression in published literature range from ≥1 to 2 dB/year loss in MD, and reported 
prevalence of patients progressing rapidly varies between 3-17% in previous studies.[154–159] 
The main strength of this study is the large starting sample size compared to others in the literature. 
Although only 205 uveitic eyes were included in the final VF progression analysis, a sufficiently large 
starting sample was required to reach the final 205 included samples. This highlights the strength of 
Big Data in carrying out this type of retrospective study. Inclusion of patients was restricted to those 
with a minimum of 4 VF tests over at least 4 years. Additionally, at least 4 of the included VF tests 
must have been performed within 4 years of the first test. As with  previous work, the minimum 
inclusion criteria was a compromise between maximising sample size whilst still ensuring robustness 
of the rate of progression estimates.[84,87] Reasons for this are given in the additional discussion 
section in Chapter 7. 
This study also has several limitations. Firstly, the data were reliant upon accurate recording in the 
EMR. Diagnostic labelling within the Medisoft EMR is not a mandatory field and can be entered as 
free-text, or not entered at all. A large list of diagnostic labels commonly found in the presence of uveitis 
was included to widen the capture of uveitis subjects. However, a large portion of uveitis subjects in 
this analysis were lacking in anatomical or disease-specific diagnostic labels in the EMR, thus limiting 
the ability to explore patterns in specific uveitis subtypes. Steps were taken in the analyses to mitigate 
the confounding effects of ocular comorbidities. For example, PoPLR VF progression analysis with PD 
values is designed to identify localised VF change and not just general reduction in VF sensitivity that 
might be attributed to developing cataract. Results from the PoPLR analysis supported the main 
findings. Nevertheless, its not possible with this data to fully account for the effects of ocular 
comorbidities on perimetric performance of the patients. Uveitic patients are susceptible to a range of 
complications such as cataract, cystoid macular edema, fibrin deposition, band keratopathy and 
epiretinal membrane, all of which may affect VF performance. Acute inflammatory processes may 
cause temporary drops in visual acuity, which subsequently resolves. This may explain why some 
patients’ MD seems to improve over time (i.e. perhaps due to cataract surgery or resolution of 
inflammatory disease such as cystoid macular oedema), although this could also be attributed to patient 
variability and learning effect.[97,98,160] On the other hand, progressive loss of visual acuity from 
longstanding uveitic damage (such as scarring and retinal atrophy) may also confound the apparent loss 
of MD in the uveitic group. Structural information such as retinal nerve fibre layer thickness, cup-to-
disc ratio or the inclusion of imaging data would be useful for differentiating between true glaucomatous 
VF loss and global loss due to other causes. Although not available in this dataset, linkage of structural 
information would be of interest for future studies. 
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An important finding is the worse presenting MD in the uveitic group, suggesting early VF loss may be 
under-detected. Additionally, the baseline age in the uveitis plus glaucoma group was younger, which 
also supports the hypothesis that uveitic glaucoma may progress faster. Detecting early VF loss is 
clinically difficult if perimetric testing is not performed routinely, particularly in the absence of a 
deranged IOP. In the context of uveitis, controlling the inflammation may require more clinical urgency 
and early glaucomatous damage can be easily overlooked. On the other hand anti-inflammatory 
treatment, of which corticosteroids is the preferred first-line agent, can precipitate raised IOP in up to a 
third of patients.[161,162] Steroid implants have been shown to increase the risk of developing 
glaucomatous optic neuropathy by four times compared to those taking systemic therapy.[163] A 
comparison of VF progression in uveitis patients receiving steroid treatment versus those without would 
be of interest for future studies. Such an analysis would require accurate data on frequency, duration 
and formulation of steroid use, which is not routinely captured by the Medisoft EMR. Successful 
management of glaucoma in uveitis requires simultaneous treatment of inflammation and IOP elevation. 
In some cases, controlling the inflammation also helps to reduce IOP and there is evidence to suggest 
those treated with aggressive anti-inflammatory therapy have better outcomes.[144] Anti-glaucomatous 
drugs such as beta-blockers and carbonic anhydrase inhibitors can be used to lower the IOP. Some 
controversy exists around the use of prostaglandin analogues (PGAs) as a first-line agent due to the 
theoretical risk of blood-aqueous barrier disruption and cystoid macular oedema, however multiple 
studies have found no differences in the rate of inflammatory recurrences and it is considered safe to 
use PGAs as first-line therapy in quiescent uveitis.[164,165] The management options for glaucoma in 
uveitis are predominantly with an aim to decrease IOP, but it is unclear whether these treatments 
influence IOP variability. 
The exact pathological process behind glaucoma in different uveitic subtypes is difficult to define, as 
there are often multiple co-existing mechanisms driving IOP changes and glaucomatous damage. Yet, 
elevated IOP has been considered the main modifiable risk factor. This study, albeit based on 
retrospective data, represents the largest published longitudinal analysis of IOP behaviour in uveitis 
patients with glaucoma. The mean longitudinal IOP was found to be similar in uveitis and POAG. 
However, IOP range and MAE was higher in uveitis patients. In both uveitic and POAG groups, IOP 
range and MAE are consistently higher in those progressing rapidly compared to those losing less than 
1.5 dB/year in MD. It is unclear whether the fluctuant IOP is a contributing factor to glaucomatous 
damage, or whether it is simply a more prevalent finding in those with more severe glaucoma, 
representing those with the poorest controlled IOP and therefore receiving the most aggressive 
treatment. The published literature on POAG is inconsistent in this area, with some studies reporting a 
strong relationship between ocular hypertension and glaucomatous field loss, whilst others suggest that 
long-term IOP variability is associated more strongly with progression than mean IOP.[166,167] Lee et 
al. suggest a 1 mmHg increase in standard deviation of IOP is associated with a four-fold increase in 
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risk of POAG progression.[168] In uveitis, published long-term data on IOP is limited and 
understanding of IOP behaviour in the context of inflammation, secondary structural damage and anti-
inflammatory treatment remains poor.  
Glaucoma secondary to uveitis is an important cause of irreversible sight loss, which is challenging to 
detect and manage. The main finding from retrospective analysis of clinical data from multi-centre 
glaucoma services in England shows that uveitis patients with glaucoma are almost twice as likely to 
lose VF rapidly when compared to patients with POAG. Therefore, clinicians managing patients with 
uveitis should remain vigilant for glaucomatous damage in these high-risk patients. In England, there 
is evidence that most patients get a similar diet of VF examinations during follow-up, and the findings 
support this.[84,110] These results at least highlight that uveitis patients require closer attention in order 
to rule out rapid loss of VF during treatment.  IOP variability is more common in uveitic eyes and the 
findings of the current study suggest that IOP fluctuates across a wider range in this group than in 
POAG. An appropriate change would be to consider implementing a low threshold for glaucoma 
screening in patients with uveitis, even if IOP is within normal limits and particularly in the presence 




6 Using electronic medical records to study socioeconomic status and 
outcomes in glaucoma clinics 
The co-authors of this work are Yusrah Shweikh (YS), Susan Bryan (SB) and David Crabb (DC). The 
analysis contained in the study (i.e. the R code for the models and the maps as well as the fusion table 
management), the production of the figures and the drafting of the manuscript was carried out by SRK. 
YS was the clinical co-author and wrote much of the introduction. The manuscript was then reviewed 
and edited by all of the authors. 
6.1 Introduction 
Glaucoma is a common eye condition with significant public health implications.  It affects around 2% 
of Caucasians over 40 and is more prevalent with increasing age and in Black populations.[169]  
Glaucoma is the most common cause of optic neuropathy and second largest cause of blindness in the 
UK, accounting for 7.6% of registration for sight impairment and 11% of severe sight impairment.[170]  
VF defects resulting from optic nerve damage are irreversible.  Late presentation with significant VF 
defects is a common problem and is a major risk factor for subsequent visual loss.[87,171,172]  
Glaucoma is mostly asymptomatic in its early stages and early detection relies on regular eye tests with 
optometrists. Over 90% of referrals to hospital eye services in the UK are generated by 
optometrists.[173] 
It is widely recognised that deprivation adversely affects health.  In studies of all-cause mortality it is 
suggested that the effects of deprivation are mediated through ‘health-related behaviours’ including 
health-seeking behaviour, smoking, diet, alcohol consumption and physical activity.[174]  The link 
between deprivation and late glaucoma presentation is well established.[175–177]  There is no formal 
screening programme for glaucoma in the UK and individuals with lower socioeconomic status, lower 
educational attainment and less awareness of eye disease and are less likely to engage with primary 
healthcare services for “opportunistic” eye health screening, recommended once every 2 years.[178]  
Fraser and colleagues reported that the risk of late glaucoma presentation was proportional to the 
number of years since the patient last visited an optometrist and also found a strong association between 
lower socioeconomic status and late glaucoma presentation.[171]  Further evidence has since emerged 
to corroborate the latter finding.[175,177,179–182]  Less is known about the effect of socioeconomic 
status on the speed (rate) of VF progression in patients who are diagnosed and receiving long-term 
treatment from Hospital eye services. Previous studies have found that the extent of VF loss at 
presentation is associated with more rapid VF loss.[183,184]  However, the impact of socioeconomic 
status per se on VF progression has not been evaluated.   
An EMR allows collection of clinical data from large patient populations. In turn these data can be used 
for identifying trends in disease progression and treatment response on a large scale.[53,66,85,185–
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187] Linking these Big Data to other public health data like those developed for measuring a person’s 
socioeconomic status opens up interesting areas of research and this study serves as an example of this. 
One such data set is the index of multiple deprivation (IMD), which is the most widely used English 
measure of socio-economic status, aimed at assisting policy makers. IMD is based on 7 metrics: income, 
employment, education, health, crime, living environment and access to housing and services.[188]  
The purpose of this study is to present large-scale multisite data on glaucoma severity at presentation 
to secondary eye care services in England and to see how this varies across the socioeconomic spectrum.  
The novel hypothesis that rates of VF progression in diagnosed patients do not vary with socioeconomic 
status is also tested, which might suggest greater equity once people are diagnosed.  
6.2 Methods 
This study involved retrospective analysis of large-scale data extracted from EMRs form several 
glaucoma clinics in England. 
For additional information regarding the datasets used in this study, see the primers for Dataset 1 and 
Dataset 2. These data included VF results as measured on the Humphrey Visual Field Analyzer (HFA, 
Carl Zeiss Meditec, Dublin, CA, USA) as well as age (years) and a minimum data set of other clinical 
records. Eyes with other ocular comorbidities (impeded fundal view etc.) were excluded based on 
coding in the EMR database. At source the EMR includes data on residential address as standard. Each 
postcode was identified and allocated to the IMD score for that area (LSOA; lower layer super output 
area) based on the English Indices of Deprivation 2015 
(https://www.gov.uk/government/statistics/english-indices-of-deprivation-2015). The LSOA 
conversion was undertaken at source to avoid transfer of patient-identifiable data. The English Indices 
of Deprivation 2015 uses the LSOAs defined in the 2011 census, with evaluation of deprivation being 
primarily based on data taken from 2012 to 2013. 
Anonymised data were collected from five regionally different National Health Service (NHS) Hospital 
Trust glaucoma clinics in England. Only VFs recorded using the 24-2 Swedish Interactive Testing 
Algorithm (SITA Standard or SITA Fast) were included for analysis. 
The study adhered to the Declaration of Helsinki and all analyses of the data were approved by a 
research ethics committee of City, University of London. All patient data were anonymized and securely 





Age, VF and IMD data were available for a total of 69,588 patients. Patients with ≥2 HFA VFs (recorded 
using the 24-2 SITA algorithm) were included for analyses on glaucoma severity at presentation 
(n=45,973). Presenting VF was defined as the VF of the second examination. This was done to 
ameliorate the bias of a perimetry learning effect. Only one eye was included per patient. The eye with 
the worse (more negative) presenting MD was chosen for inclusion. This is to be interpreted as a 
surrogate of disease presentation. The worse eyes were chosen as a surrogate of the most “detectable” 
level of VF loss. Eyes were excluded if they had an impeded fundal view, vitreous opacities or previous 
retinal detachments, resulting in 324 eyes being removed (n=45,649).  
Patients were stratified into their IMD quintiles (1-5). Quintile 5 corresponds to the most deprived 
group. Odds ratios were calculated to estimate the relative likelihood that patients in the different 
quintiles presented with severe MD loss (-12 dB or worse) relative to the middle (third) quintile. To do 
this, a logistic regression model, adjusted for age, was fitted with the third IMD quintile set as the 
reference group. A higher odds ratio ( >1) for a more deprived quintile would indicate a relationship 
between deprivation and late presentation (Figure 6.1). Secondary analyses using IMD deciles (1-10) 
were also carried out. In these analyses, the fifth IMD decile was set as the reference group (Figure 6.2).  
Longitudinal analysis 
Patients with ≥6 VFs were included for analyses on VF progression (n=16,507). As with the cross-
sectional analysis, only one eye was included per patient (the eye with the lower MD value at 
presentation). 
Speed (rate) of MD loss per year was calculated by ordinary least squares linear regression of MD over 
time, for those with sufficient follow-up visits to be included in the progression analyses. As before, 
patients were stratified into IMD quintiles (1-5). Odds ratios were used to estimate the relative 
likelihood that patients in different IMD quintiles had a rapid rate of MD loss (-1.5 dB per year or 
worse) relative to the third quintile. A logistic regression model, adjusted for age, was fitted with the 
third IMD quintile set as the reference group. A positive odds ratio (>1) would indicate that a particular 
quintile is more likely to have a rapid rate of MD loss relative to the reference group (Figure 6.3).  
Secondary longitudinal analyses replacing IMD quintiles with IMD deciles were also completed. The 
reference group of the logistic regression model was set to the fifth decile (Figure 6.4).  
All statistical analyses were done using R (R Development Core Team, R: A Language and 





A total of 45,694 (65.6%) patients were included for the analysis of glaucoma severity at presentation. 
Summary measures of patients included in the cross-sectional analysis are given in Table 6.1.  
Table 6.1: Table showing summary statistics of patients included in the cross-section analysis. 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 Total 
Median age at 
presentation 
(IQR) (years) 
69 (60, 77) 68 (59, 77) 69 (59, 77) 69 (58, 77) 69 (60, 77) 69 (59, 77) 















% of patients 
presenting worse 
than -12 dB MD 
11.8 12.5 14.4 14.6 17.0 13.3 
 
A total of 16,507 (23.7%) patients were included for the rates of progression (longitudinal) analysis. 




Table 6.2: Table showing the summary statistics of patients included in the longitudinal analysis. 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 Total 
Median age at 
presentation 
(IQR) (years) 
68 (60, 76) 68 (59, 75) 68 (60, 76) 68 (60, 76) 68 (59, 76) 68 (60, 
75) 
















% of patients 
progressing faster 
than -1.5 dB/year 
11.3 11.1 12.0 12.5 11.5 11.6 
 
The odds ratio of presenting with a MD of ≤-12dB was 1.3 for the most deprived quintile (quintile 5, 
relative to reference quintile 3) versus an odds ratio of 0.8 for patients in least deprived quintile (quintile 
1, relative to reference quintile 3), p<0.01 (Figure 6.1). This shows that patients from deprived regions 
are significantly more likely to present with severe MD loss than patients from more affluent regions. 
Figure 6.1: Ratio of patients presenting with severe glaucoma (worse than -12 dB MD in worse eye) 
per IMD quintile relative to the middle (third) quintile. The numbers of stars at the top of the plot 






Figure 6.2: Ratio of patients presenting with severe glaucoma (worse than -12 dB MD in worse eye) 
per IMD quintile relative to the fifth decile. The numbers of stars at the top of the plot indicate the level 
of significance, with three stars (***) representing a value of p < 0.001. 
A total of 16,507 patients were included for the analysis of VF progression. Figure 6.3 shows that IMD 
segregated by quintiles had no significant effect relative to the central quintile on rapid VF progression. 
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This indicates that although presenting MD is associated with deprivation, once patients are in the 
glaucoma clinics, deprivation does not affect their progression. 
Figure 6.3: Ratio of patients with a fast ( <-1 dB/year) rate of VF loss per IMD quintile relative to the 
middle (third) quintile. The lack of stars (***) indicate that none of the quintiles were statistically 




Figure 6.4: Ratio of patients with a fast ( <-1 dB/year) rate of VF loss per IMD decile relative to the 
fifth decile. The lack of stars (***) indicate that none of the deciles were statistically significantly 






Using data from 45,649 patients in glaucoma clinics across the UK, this study has shown that people 
with greater deprivation are more likely to present to hospital eye services with more advanced 
glaucoma. An analysis of VF progression was carried out using data from 16,507 patients, which 
revealed that IMD had no significant impact on rates of progression .  Deprivation as indicated by IMD 
segregated by quintiles also had no significant effect on rates of progression (Figure 6.3).  
A strength of this study is the sample size, allowing us to detect and quantify small effects.  Patients 
with obvious confounders including patients with no fundal view and those with a history of retinal 
detachment were excluded. However, data on systemic and ocular comorbidities are incomplete and 
have made an assumption that the VF defects of patients in glaucoma clinics are reliable and are 
secondary to glaucoma.  Another source of potential bias is the assumption that initial VFs represent 
those of a new patient in every case when they may be those of a patient transferred from a different 
glaucoma unit.  However, the number of transferred cases is expected to be relatively low and expect 
that this would not diminish the overall patterns seen in the data.   
Analysis of large-scale data in this study supports the previously published finding that patients with 
greater deprivation are more likely to present to hospital eye services with more severe 
glaucoma.[175,177,189]  Fraser and colleagues reported a case control study in 1999 in which an 
association between lower socioeconomic status and late glaucoma presentation was identified.[171]  
In 2009 and 2010 supporting evidence was published by two UK groups.[177,189]  Limitations of the 
study by Fraser and colleagues are the small sample size of 110 cases and the relative lack of resolution 
of the Jarman index used which is a composite measure of 3 factors (occupation, housing and access to 
a car).  The relatively low power of this study may explain the reported lack of statistical significance 
in some domains.  The studies published in 2009 also report small sample sizes of 126 and 113 patients 
respectively.[177,189]  The theory that deprivation is linked to late glaucoma presentation is also 
supported by literature from Canada, where patients from more affluent neighbourhoods were 
statistically less likely to have moderate or severe glaucoma at initial presentation.[181]  As a novel 
finding, this study has also identified no significant relationship between the rate of VF progression and 
socioeconomic deprivation (Figure 6.3). This may be a result of care in the NHS being free at the point 
of service. In countries where patients must pay out of pocket for care, it’s possible that this relationship 
wouldn’t hold. A systematic review found that the cost of illness for glaucoma increases with severity, 
so presenting with late stage disease would further compound the burden of disease.[190] Further 
discussion on this can be found in Chapter 7.    
Results from this study suggest that patients with lower socioeconomic status are at no greater risk of 
glaucomatous VF progression while under the care of glaucoma clinics compared to patients with less 
deprivation, despite a greater likelihood of presenting with severe glaucoma. Late glaucoma 
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presentation can be explained by less frequent attendance to optometrists, failure of glaucoma detection 
by optometrists or inherently more aggressive disease.[171,175]  The evidence that there is a mismatch 
between the locations of optometrists and areas of deprivation within the UK is inconclusive, but it is 
possible that a limited access to primary care services in socioeconomically disadvantaged areas is 
contributing to these findings.[191,192] Previous research also links deprivation and lower educational 
attainment to diminished access to eye care services.[193,194]  Reasons underpinning poor access to 
regular eye testing with optometrists in the UK are varied and may include poor knowledge of eye 
health, fear, inertia, perceived costs, limited mobility and challenging geographical access.[195,196]  
Directing resources into case-finding and strengthening links between primary and secondary eye care 
may help reduce the disparity in severity at presentation between socioeconomic groups. For the most 
economically disadvantaged areas, there may be a role for non-commercial primary eye care that is not 
funded by examination fees or product sales.[191] The choice of service locations could be facilitated 
by interactive maps generated by further work in this area. The costs of such services would be offset 





7 Overview, further discussion of main findings and future work 
7.1 Overview of findings  
Firstly, I want to start with a general critique and discussion of the studies conducted in this thesis. In 
any of the chapters that make use of a longitudinal analysis of visual fields, the inclusion criteria of 
which visits and how many visits to include changes seemingly at random. One could be forgiven for 
thinking that the intent behind this was some form of “p-hacking” or other untoward data manipulation. 
In Chapter 2 and 6, I chose to include six visits and then excluded the first one to mitigate learning 
effects. In Chapter 3, there is a requirement of at least four visits but without an upper limit on how 
many to include, so that some patients have four and others have ten. In Chapter 5 it is at least four 
visits in a four-year window, but the first is not excluded. The obvious question is why? The answer 
lies in trying to strike a balance between statistical power and inclusion. If one assumes that VF loss is 
linear then the number of visits needed to detect the rate of progression is determined by the rate of 
progression itself (steeper slopes are easier to detect), the variability (less noise makes for a more 
accurate model) and the length of time between visits (longer time makes it easier to detect change). 
For a single visual field series, it takes about six evenly spaced VF measurements over two years to 
detect a rate of progression with a relatively moderate level of variability with 80% power.[6] It’s 
possible to get the same power with four VF measurements but spaced out over a longer time period 
(say 3 or 4 years). To emphasise the point I’m trying to make, imagine a scenario where it’s only 
possible to schedule two VF visits. To use two VF measurements to detect VF loss, those two VFs need 
to be spread out far enough apart to be able to detect a certain level of change but not far enough that 
the person being measured could have reasonably lost a large chunk of VF function. This is in essence 
the basis of recommendations for setting guidelines on the intervals between VF visits. When carrying 
out comparisons of these slopes, another level of variability arises. When comparing two groups, each 
group will have an underlying distribution of these slopes. The more observations (patients) in each of 
these groups, the easier it is to determine what that underlying distribution is. How close the study 
sample can get to the “true” underlying distribution using a limited number of observations is a process 
that can be tweaked by choosing particular inclusion criteria and statistical methods.  
If there is an abundance of data, it doesn’t really matter what your inclusion criteria is. If the slopes 
(that is, the rates of progressions) really are different, then a change will be detected given enough data 
(provided it isn’t systematically biased in some way). In Chapters 3 and 6, the subpopulations that are 
being studied (patients in clinics and patients in different SES groupings respectively) are so large that 
not much thought needs to go into how many VFs are needed to be included. With thousands of patients 
in each group, even with high levels of variability a crude mean estimate will be decently accurate. In 
Chapter 5 however, the subgroup is much smaller than in the previous chapters. A mixed effects model 
is used so that no useful information about intra-patient variability is lost. If all the chapters had used 
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this approach, the results might not have changed much but the certainty would have gone up. There 
are two main reasons that this was not done. The first is for interpretability, simple linear models are 
more easily understood than mixed effects models. If the goal of this thesis is to demonstrate how useful 
Big Data is, it’s important that readers are easily able to understand the methods and results. Secondly, 
it highlights (albeit indirectly) the power of large data sets. In clinical trials, a lot of effort goes into 
planning the analysis that will be carried out, how many patients are needed, how far apart and how 
frequently to test the VF etc.[91,197] This is because clinical trials are expensive. In studies using Big 
Data (i.e. an abundance of data), a blunt tool (OLS linear models) can be used and still come away with 
a statistically significant result. This further emphasises a need to move away from relying on p-values 
and instead focus on how meaningful a result is in context. The issue of significance versus relevance 
arises in Chapter 2.In the chapter, several aspects of  perimetry procedure were analysed using a large 
VF dataset. Patients who had a series of at least 6 pairs of monocular VF tests, where the right eye was 
consistently tested first were included in the study (n=6320 One of the aims of the study was to 
determine if the testing order of eyes effected their perimetric performance, and if so, by how much. 
The results showed a small decrease (0.13 dB, 95% CI: -0.26, -0.02) in MD in the second eye tested 
compared to the first and a small relative (3%) increase in variability. The effect is small but is also an 
average across thousands of patients. The spread of variability is large and so does not say much on 
how any individual patient might vary. While statistically significant, this result is not directly clinically 
useful although in situations where measurement precision and intrapatient variability needs to be kept 
constant, it may be beneficial to keep the order of testing constant.  
A criticism that was raised about the usefulness of the type of clinic-based Big Data found in this thesis 
is of its veracity. A reviewer commenting on the now-published version of Chapter 5 argued that relying 
on diagnostic information contained in EMRs alone is not a basis for a study and needs to be validated 
by reviewing charts. I think criticisms such as these are a part of a series of growing pains associated 
with moving towards electronic based systems. Issues around clinicians recording conditions in 
different ways (such as the different subtypes of uveitis) can be overcome by implementing standardised 
criteria such as The Standardisation of Uveitis Nomenclature criteria in all clinics. Most specialists are 
aware of these and once EMRs have the appropriate labels in their systems, it is then just a case of 
adaptation. There is a potential for systematic biases between centres due to different systems and 
practices (discussed below). A national unified standardisation of EMR systems and procedures would 
address this in the future, but for the time being, as long as centres are measuring and recording the 
same data, it’s possible to collate them into a single dataset with some harmonisation. Chapter 5 
investigated cases of patients with uveitis and glaucoma. A treatment for uveitis (steroids) can increase 
IOP and lead to glaucoma, making it difficult to manage patients who have both. The results of a mixed 
effects model showed that the uveitis and glaucoma group had a higher rate of progression when 
adjusted for age (-0.49 dB/year vs -0.37 dB/year, p < 0.01). The uveitis and glaucoma group also had 
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twice the risk (Age-adjusted Risk Ratio: 1.9) of being “fast progressors” (progressing faster than -1.5 
dB/year). Many of the IOP metrics showed a statistically significant association with the combination 
group and the fast progressors. Namely, the combination group had a higher variability (MAE) 
compared to the POAG group and the fast progressors had a wider range of IOP values compared to 
the non-fast progressors. It would have been of interest to do an analysis of the subtypes of uveitis but 
the sample sizes were too small. This was due to (in part) almost half of the patients being labelled as 
having a uveitis comorbidity, but not specifying the subtype. If standardised criteria as mentioned 
previously had been implemented previously, this data may have been available. 
 
The study in Chapter 3 looked at how Big Data coming from glaucoma clinics can be used to audit 
health service delivery of the clinics themselves. This was done by proposing 6 metrics that could  be 
used to get a snapshot view of how a clinic or sample population is performing. One-third of people 
(34.8%) in the EMRs had measurable and repeatable VF loss and were subject to analyses (n=25 760 
patients). The median (IQR) age and presenting MD in these patients were 71 (61, 78) years and −6 (–
10, –4) dB, respectively. In the 19,264 patients with more than 4 years follow-up, the median (IQR) rate 
of MD loss was −0.2 (−0.8, 0.3) dB/year and the median (IQR) intervals between VF examinations was 
11 (8, 16) months. Metrics predicting loss of sight years and reliability of examinations varied between 
centres (p<0.001). This study illustrates the feasibility of assessing aspects of health service delivery in 
glaucoma clinics through analysis of VF databases. Proposed metrics could be useful for blindness 
prevention from glaucoma in secondary care centres.  In the discussion section it was noted that there 
was a significant variability in results between the centres. There are essentially two main reasons that 
there would be measurable VF differences between the centres. With everything else equal, either the 
underlying populations are different, or the management of the patients is different. In this study take 
Centres 1 and 5 as examples and compare their rates of progression (-0.37 vs -0.10 dB/year). The reason 
for this difference could be because Centre 5 is much better at managing glaucoma patients or, more 
likely, it is because of a demographic difference. Centre 1 has an older population and a higher 
percentage of patients presenting with later stage VF damage. Both of these could be contributory 
factors to patients in that centre progressing at a faster rate compared to Centre 5. The true answer is 
likely a combination of both factors. For a true fair combination between centres, a multivariable model 
correcting for demographic factors would need to be used. This raises a broader point on creating data 
sets from multiple sources, such as in clinical trials with multiple centres or indeed observational data 
from multiple clinics. Systematic biases arise when there is a non-random reason for changes in the 
measurement or recording of data in a sample. A common example given is of a response bias in 
surveys. With regards to VF testing, if some centres used an opaque eyepatch and others used a 
translucent patch, this could (and likely would) lead to a difference in MD (see discussion of Chapter 
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2). When collating data from different centres such as in this study, it is important to keep this in mind 
when carrying out analyses.  
The work in Chapter 4 replicates the findings of several large-scale clinical trials on the conversion 
from OHT to POAG. Clinical trials are of course the gold standard in determining the efficacy of 
medical treatments, but it is not clear how well the results from trials are replicated in clinics. For the 
sake of rigor, clinical trials are stringently monitored but the “real world” in-clinic conditions tend to 
be a bit messier. Studies using Big Data to replicate the results of clinical trials using a population from 
clinics undergoing routine treatment are a useful resource in determining the utility of interventions 
outside of a clinical trial. The cumulative risk of conversion to POAG was 17.5% (95% CI: 15.4% – 
19.6%) at 5 years for this in-clinic population. Older age (HR: 1.35 per decade, 95% CI: 1.22 – 1.50, P 
< 0.001) was associated with a higher risk of conversion. IOP-lowering therapy (HR: 0.45, 95% CI: 
0.35 – 0.57, P < 0.001) was associated with a lower risk of conversion. The discussion in Chapter 4 
compares these results to that of the OHTS study. Both in this study and in the OHTS, IOP lowering 
treatment was associated with around a 50% reduction in conversion to POAG over five years. In this 
instance, the in-clinic efficacy lined up with that of a major clinical trial but this is not guaranteed. 
Further replication studies in the same vein are needed and could be the topics of future work.  
In Chapter 6, the two main datasets in the thesis were used in combination with census statistics to take 
a closer look at socioeconomic factors and how they affect certain aspects of glaucoma diagnosis and 
management. The linked dataset (Dataset 2, which contains IMD data) was used to calculate odds ratios. 
Different socioeconomic groups were grouped into quintiles and their relative odds of late presentation 
to clinic were calculated (n=45649). Secondary analysis comparing their rates of progression was also 
carried out (n=16507). The most deprived quintile of the population presented to clinics with a 
statistically significantly worse baseline MD than the reference (middle) quantile (p < 0.001). There 
was no difference in rates of progression between quintiles. This indicates that once patients were in 
the hospital eye services, socioeconomic status did not affect outcomes. It is possible that the UK 
(England) is a special case in that the NHS provides care free at the point of service. One study for 
Korea found similar results. Those with lower incomes were more likely to have glaucoma related visual 
impairment but that there was no significant difference in impairment after they were diagnosed and 
managed.[198] Like the UK, Korea has a universal health scheme and the cost of treatment was mostly 
covered. In countries where patients must pay out of pocket this may not necessarily be true. One 
American study found that ethnic minorities (black race and Latino ethnicity) were much more likely 
to be inconsistent with follow-up glaucoma appointments.[199] While self-reported ability to pay for 
medications was not reported to be predictive of irregular follow-up patterns, the sample size was small 
and most participants had the same government-provided insurance. Of the 152 patients only 9 had 
private insurance or no insurance making it difficult to draw any definite conclusions. The author echoes 
the above hypothesis that ability to pay may be a factor in glaucoma adherence. Reiterating a US 
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department of health and human services report stating that “patients of lower socioeconomic status are 
more likely to have limited access to care” the authors conclude: “whether similar patterns are evident 
in patients with glaucoma … is an area for future investigation”. 
7.2 Ideas for future work 
The studies in this thesis go some of way towards demonstrating the breadth of analysis that can be 
carried out with these types of large-scale clinic data. Much of the data, particularly in Dataset 2 has 
the potential to be used in numerous more studies. Many additional projects were touched upon during 
the course of compiling the work in this thesis and several of the studies and could potentially lead to 
interesting and impactful work. A systematic review analysing the challenges of Big Data in healthcare 
listed issues around data structure, security, data standardisation and storage/transfers as the biggest 
barriers to effective research.[200] Several of these challenges needed to be overcome to produce the 
work contained in this thesis.  
One study, for example, was to investigate how well the whole point-wise VF could be predicted by 
only using the first (or first few) examination results. There were several potential approaches ranging 
from simple linear models to more complicated deep learning techniques. A recent paper used deep 
learning techniques to create a model that could predict a patient’s pointwise VF results.[201] This work 
had around 30,000 patients with VF records while the two datasets used in this thesis alone amounts to 
well over four times that (>120000), as well as a large portion of them including additional linked data. 
These datasets (in particular Dataset 2) would be incredibly useful in any sort of deep learning not only 
for the sheer number of patients/VFs but also the linked data which adds additional dimensionality. As 
many of these sophisticated computer-science techniques are relatively new to ophthalmology, many 
simple but useful studies could be readily done and be of high interest. 
Another example which would benefit from large scale VF data would be a study of perimetric 
variability based on age. Large sample sizes are needed to better understand small variation in 
populations based on factors like age or ethnicity. When there are large sets of data available, 
monitoring and treatment could potentially be personalised to some extent to make the process more 
efficient. The linked dataset for example contains information on conditions such as cataract surgery, 
diabetes status, previous retinal detachment and mortality status (at the time of extraction in 2015). 
Many short and interesting studies could be carried out looking at factors such as these and what 
association, if any, they have on glaucoma metrics (VF, IOP, etc.).  
In Chapter 2, an order effect was investigated using one measure of longitudinal variability, namely 
MAE. Many other measures of reliability (such as false-positives, false-negatives and fixation loss) 
could be used to explore slightly different aspects of the variability. Perimetric variability is associated 
disease severity and it’s also possible that it is associated with age. A more complex model, such as a 
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mixed-effects model, could be used to further investigate factors behind this order effect. It is likely, 
however, that any subsequent effect found would be similarly small and possibly not of clinical 
relevance. 
In Chapter 3, six metrics were chosen to try to quantify how well clinics were performing and how well 
patients’ outcomes were. To an extent, these metrics were chosen arbitrarily and other outcomes could 
have been chosen instead. One example of a different metric would be to analyse the rates and outcomes 
of glaucoma surgeries in the clinics. Other data from Dataset 2, such as rates of medical treatment, 
ethnicity and IOP measures could also be included to gain insights about different aspects of the clinic. 
In Chapter 4, clinic data was used to estimate the “real-world” conversion rate from OHT to POAG in 
the HES. What was not reported were the differences, if any, that existed between the clinics in rates of 
conversion. Health economic factors, such as the cost of monitoring/treating OHT patients and 
epidemiological factors such as the numbers of OHT patients needed to treat to prevent an additional 
conversion could also be estimated using these data. Additional medications (such as systemic 
medications like Acetazolamide) or combinations of medications could also be explored to see what 
effect they have on OHT conversion rates. 
In Chapter 5, a broad umbrella term of “uveitis” was used to categories the groups. Uveitis itself has 
several subtypes based on where inflammation occurs (anterior, posterior etc.). It is likely the case that 
some of these sub-types have a more profound effect on VF outcomes than others and additional work 
to explore this could prove to be fruitful. Unfortunately, due to a low number of patient data with these 
anatomical subtypes in this dataset, it wasn’t possible to consider this during the course of the study. 
Future ophthalmology clinic extractions, especially clinics that specialise in uveitis, may provide the 
additional patients needed for this type of sub-analysis. Further work could also be done to expand on 
the IOP metrics, as well as to include information about medications and surgeries into the model. 
Qualitative work on the experience of uveitis patients with this condition could be carried out in the 
future. Dealing with glaucoma or uveitis alone can be a burden for patients so it’s likely that a 
combination of both would be more so. Reaching out to uveitis support groups could be a potential 
avenue for further study. 
In Chapter 6, one measure of socioeconomic deprivation (IMD) was used to investigate the effect of 
socioeconomic status on glaucoma presentation and progression. This metric, while useful, hides a lot 
of underlying information. The score itself is made up of seven sub-scores relating to factors like 
education and crime. When using IMD alone it may obfuscate a specific aspect of deprivation that is 
driving the late presentation. One idea to tackle this would be to instead use the original seven scores, 
increasing the resolution of study and potentially teasing out the specific factors affecting late 
presentation to eye clinics. Another and potentially more interesting metric would be to use the ACORN 
(A Classification Of Residential Neighbourhoods) segmentation tool, which categorises the UKs 
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population into demographic types based on behaviour as well as where they live.[202] Often used 
commercially for marketing purposes, it combines several public and private datasets to attempt to 
capture insights about populations. Categories such as “First time buyers in small, modern homes”, 
“Semi-skilled workers in traditional neighbourhoods” or “elderly people in social rented flats” would 
be a much more intuitive way to convey the lifestyles of people interacting with eye services than a 
single number. 
Hopefully it is clear that Big Data and the inclusion of more sophisticated analyses have the potential 
to change the way providers leverage modern computing power to make more informed clinical 
decisions. To make this transition as easy as possible, the large amounts of data being collected within 
healthcare need to be organised and structured in such a way to make it accessible to clinicians and 
researchers. This will pave the way to a future where Big Data analytics is synonymous with healthcare 
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